1
|
Zhang T, Zhou C, Guo J, Chang J, Wu H, He J. RTEL1 gene polymorphisms and neuroblastoma risk in Chinese children. BMC Cancer 2023; 23:1145. [PMID: 38001404 PMCID: PMC10675872 DOI: 10.1186/s12885-023-11642-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2023] [Accepted: 11/14/2023] [Indexed: 11/26/2023] Open
Abstract
BACKGROUND Neuroblastoma, a neuroendocrine tumor originating from the sympathetic ganglia, is one of the most common malignancies in childhood. RTEL1 is critical in many fundamental cellular processes, such as DNA replication, DNA damage repair, genomic integrity, and telomere stability. Single nucleotide polymorphisms (SNPs) in the RTEL1 gene have been reported to confer susceptibility to multiple cancers, but their contributing roles in neuroblastoma remain unclear. METHODS We conducted a study on 402 neuroblastoma cases and 473 controls to assess the association between four RTEL1 SNPs (rs3761124 T>C, rs3848672 T>C, rs3208008 A>C and rs2297441 G>A) and neuroblastoma susceptibility. RESULTS Our results show that rs3848672 T>C is significantly associated with an increased risk of neuroblastoma [CC vs. TT/TC: adjusted odds ratio (OR)=1.39, 95% confidence interval (CI)=1.02-1.90, P=0.038]. The stratified analysis further indicated that boy carriers of the rs3848672 CC genotype had a higher risk of neuroblastoma, and all carriers had an increased risk of developing neuroblastoma of mediastinum origin. Moreover, the rs2297441 AA genotype increased neuroblastoma risk in girls and predisposed children to neuroblastoma arising from retroperitoneal. CONCLUSION Our study indicated that the rs3848672 CC and rs2297441 AA genotypes of the RTEL1 gene are significantly associated with an increased risk of neuroblastoma in Chinese children in a gender- and site-specific manner.
Collapse
Affiliation(s)
- Ting Zhang
- Department of Clinical Laboratory, The Affiliated Wenling Hospital of Wenzhou Medical University, Taizhou, 317500, Zhejiang, China
| | - Chunlei Zhou
- Department of Pathology, Children's Hospital of Nanjing Medical University, 72 Guangzhou Road, Nanjing, 210008, Jiangsu, China
| | - Jiejie Guo
- Department of Clinical Laboratory, The Affiliated Wenling Hospital of Wenzhou Medical University, Taizhou, 317500, Zhejiang, China
| | - Jiamin Chang
- Department of Pediatric Surgery, Guangzhou Institute of Pediatrics, Guangdong Provincial Key Laboratory of Research in Structural Birth Defect Disease, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangdong Provincial Clinical Research Center for Child Health, 9 Jinsui Road, Guangzhou, 510623, Guangdong, China
| | - Haiyan Wu
- Department of Pathology, Children's Hospital of Nanjing Medical University, 72 Guangzhou Road, Nanjing, 210008, Jiangsu, China.
| | - Jing He
- Department of Clinical Laboratory, The Affiliated Wenling Hospital of Wenzhou Medical University, Taizhou, 317500, Zhejiang, China.
- Department of Pediatric Surgery, Guangzhou Institute of Pediatrics, Guangdong Provincial Key Laboratory of Research in Structural Birth Defect Disease, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangdong Provincial Clinical Research Center for Child Health, 9 Jinsui Road, Guangzhou, 510623, Guangdong, China.
| |
Collapse
|
2
|
Wu Y, Zhou J, Zhang J, Tang Z, Chen X, Huang L, Liu S, Chen H, Wang Y. Pertinence of glioma and single nucleotide polymorphism of TERT, CCDC26, CDKN2A/B and RTEL1 genes in glioma: a meta-analysis. Front Oncol 2023; 13:1180099. [PMID: 37746290 PMCID: PMC10512948 DOI: 10.3389/fonc.2023.1180099] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2023] [Accepted: 08/08/2023] [Indexed: 09/26/2023] Open
Abstract
Background Previous genetic-epidemiological studies considered TERT (rs2736100), CCDC26 (rs4295627), CDKN2A/B (rs4977756) and RTEL1 (rs6010620) gene polymorphisms as the risk factors specific to glioma. However, the data samples of previous genetic-epidemiological studies are modest to determine whether they have definite association with glioma. Method The study paid attention to systematically searching databases of PubMed, Embase, Web of Science (WoS), Scopus, Cochrane Library and Google Scholars. Meta-analysis under 5 genetic models, namely recessive model (RM), over-dominant model (O-DM), allele model (AM), co-dominant model (C-DM) and dominant model (DM) was conducted for generating odds ratios (ORs) and 95% confidence intervals (CIs). That was accompanied by subgroup analyses according to various racial groups. The software STATA 17.0 MP was implemented in the study. Result 21 articles were collected. According to data analysis results, in four genetic models (AM, RM, DM and C-DM) TERT gene rs2736100 polymorphism, CCDC26 gene rs4295627 polymorphism, CDKN2A/B gene rs4977756 polymorphism and RTEL1 gene rs6010620 polymorphisms increased the risk of glioma in Caucasians to different degrees. In Asian populations, the CCDC26 gene rs4295627 polymorphism and CDKN2A/B gene rs4977756 polymorphism did not exhibit a relevance to the risk of glioma. It is suggested to cautiously explain these results as the sample size is small. Conclusion The current meta-analysis suggested that the SNP of TERT (rs2736100), CCDC26 (rs4295627), CDKN2A/B (rs4977756) and RTEL1 (rs6010620) genes in glioma might increase risk of glioma, but there are ethnic differences. Further studies evaluating these polymorphisms and glioma risk are warranted.
Collapse
Affiliation(s)
- Yaqi Wu
- Department of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Jun Zhou
- Department of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Jun Zhang
- Department of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Zhijian Tang
- Department of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Xi Chen
- School of Health, Brooks College, Sunnyvale, CA, United States
- Department of Epidemiology and Statistics, School of Public Health, Medical College, Zhejiang University, Hangzhou, China
| | - Lulu Huang
- Medical Affairs, the Department of ICON Pharma Development Solutions (IPD), ICON Public Limited Company (ICON Plc), Beijing, China
| | - Shengwen Liu
- Department of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Hong Chen
- Dediatric Department, School of Clinical Medicine for Women and Children, China Three Gorges University, Yichang Maternal and Child Health Hospital, Yichang, China
| | - Yu Wang
- Department of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| |
Collapse
|
3
|
Howell AE, Relton C, Martin RM, Zheng J, Kurian KM. Role of DNA methylation in the relationship between glioma risk factors and glioma incidence: a two-step Mendelian randomization study. Sci Rep 2023; 13:6590. [PMID: 37085538 PMCID: PMC10121678 DOI: 10.1038/s41598-023-33621-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2022] [Accepted: 04/15/2023] [Indexed: 04/23/2023] Open
Abstract
Genetic evidence suggests glioma risk is altered by leukocyte telomere length, allergic disease (asthma, hay fever or eczema), alcohol consumption, childhood obesity, low-density lipoprotein cholesterol (LDLc) and triglyceride levels. DNA methylation (DNAm) variation influences many of these glioma-related traits and is an established feature of glioma. Yet the causal relationship between DNAm variation with both glioma incidence and glioma risk factors is unknown. We applied a two-step Mendelian randomization (MR) approach and several sensitivity analyses (including colocalization and Steiger filtering) to assess the association of DNAm with glioma risk factors and glioma incidence. We used data from a recently published catalogue of germline genetic variants robustly associated with DNAm variation in blood (32,851 participants) and data from a genome-wide association study of glioma risk (12,488 cases and 18,169 controls, sub-divided into 6191 glioblastoma cases and 6305 non-glioblastoma cases). MR evidence indicated that DNAm at 3 CpG sites (cg01561092, cg05926943, cg01584448) in one genomic region (HEATR3) had a putative association with glioma and glioblastoma risk (False discovery rate [FDR] < 0.05). Steiger filtering provided evidence against reverse causation. Colocalization presented evidence against genetic confounding and suggested that differential DNAm at the 3 CpG sites and glioma were driven by the same genetic variant. MR provided little evidence to suggest that DNAm acts as a mediator on the causal pathway between risk factors previously examined and glioma onset. To our knowledge, this is the first study to use MR to appraise the causal link of DNAm with glioma risk factors and glioma onset. Subsequent analyses are required to improve the robustness of our results and rule out horizontal pleiotropy.
Collapse
Affiliation(s)
- Amy E Howell
- Brain Tumour Research Centre, Institute of Clinical Neurosciences, University of Bristol, Bristol, UK
| | - Caroline Relton
- MRC Integrative Epidemiology Unit (IEU), Bristol Medical School, University of Bristol, Oakfield House, Oakfield Grove, Bristol, BS8 2BN, UK
| | - Richard M Martin
- MRC Integrative Epidemiology Unit (IEU), Bristol Medical School, University of Bristol, Oakfield House, Oakfield Grove, Bristol, BS8 2BN, UK
- National Institute for Health Research (NIHR) Bristol Biomedical Research Centre, University Hospitals Bristol and Weston NHS Foundation Trust and University of Bristol, Bristol, UK
| | - Jie Zheng
- MRC Integrative Epidemiology Unit (IEU), Bristol Medical School, University of Bristol, Oakfield House, Oakfield Grove, Bristol, BS8 2BN, UK.
- Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai National Center for Translational Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
| | - Kathreena M Kurian
- Brain Tumour Research Centre, Institute of Clinical Neurosciences, University of Bristol, Bristol, UK.
| |
Collapse
|
4
|
Samanic CM, Teer JK, Thompson ZJ, Creed JH, Fridley BL, Burt Nabors L, Williams SL, Egan KM. Mitochondrial DNA sequence variation and risk of glioma. Mitochondrion 2022; 63:32-36. [PMID: 35032707 PMCID: PMC8885975 DOI: 10.1016/j.mito.2022.01.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2021] [Revised: 01/04/2022] [Accepted: 01/10/2022] [Indexed: 01/03/2023]
Abstract
BACKGROUND Malignant gliomas are the most common primary adult brain tumors, with a poor prognosis and ill-defined etiology. Mitochondrial DNA (mtDNA) sequence variation has been linked with certain cancers; however, research on glioma is lacking. METHODS We examined the association of common (minor allele frequency ≥ 5%) germline mtDNA variants and haplogroups with glioma risk in 1,566 glioma cases and 1,017 controls from a US case-control study, and 425 glioma cases and 1,534 matched controls from the UK Biobank cohort (UKB). DNA samples were genotyped using the UK Biobank array that included a set of common and rare mtDNA variants. Risk associations were examined separately for glioblastoma (GBM) and lower grade tumors (non-GBM). RESULTS In the US study, haplogroup W was inversely associated with glioma when compared with haplogroup H (OR = 0.43, 95%CI: 0.23-0.79); this association was not demonstrated in the UKB (OR = 1.07, 95%CI: 0.47-2.43). In the UKB, the variant m.3010G > A was significantly associated with GBM (OR = 1.32; 95%CI: 1.01-1.73; p = 0.04), but not non-GBM (1.23; 95%CI: 0.78-1.95; p = 0.38); no similar association was observed in the US study. In the US study, the variant m.14798 T > C, was significantly associated with non-GBM (OR = 0.72; 95%CI: 0.53-0.99), but not GBM (OR = 0.86; 95%CI: 0.66-1.11), whereas in the UKB, a positive association was observed between this variant and GBM (OR = 1.46; 95%CI: 1.06-2.02) but not non-GBM (OR = 0.92; 95%CI: 0.52-1.63). None of these associations were significant after adjustment for multiple testing. CONCLUSION The association of inherited mtDNA variation, including rare and singleton variants, with glioma risk merits further study.
Collapse
Affiliation(s)
- Claudine M Samanic
- Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center, Tampa, FL, United States
| | - Jamie K Teer
- Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center, Tampa, FL, United States
| | - Zachary J Thompson
- Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center, Tampa, FL, United States
| | - Jordan H Creed
- Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center, Tampa, FL, United States
| | - Brooke L Fridley
- Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center, Tampa, FL, United States
| | - L Burt Nabors
- Division of NeuroOncology, Department of Neurology, University of Alabama at Birmingham, 510 20th Street South, Faculty Office Tower Suite 1020 Birmingham, Birmingham, AL, United States
| | - Sion L Williams
- UM-CFAR/Sylvester CCC Argentina Consortium for Research and Training in Virally Induced AIDS-Malignancies University of Miami Miller School of Medicine, Miami, FL, United States; Neurology Basic Science Division, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, United States
| | - Kathleen M Egan
- Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center, Tampa, FL, United States
| |
Collapse
|
5
|
CD40 Pathway and IL-2 Expression Mediate the Differential Outcome of Colorectal Cancer Patients with Different CSF1R c.1085 Genotypes. Int J Mol Sci 2021; 22:ijms222212565. [PMID: 34830445 PMCID: PMC8622906 DOI: 10.3390/ijms222212565] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2021] [Revised: 11/18/2021] [Accepted: 11/18/2021] [Indexed: 01/31/2023] Open
Abstract
Colony-stimulating factor 1 receptor (CSF-1R) acts as the receptor for colony stimulating factor 1, a cytokine that controls the production, differentiation, and function of macrophages. Prior studies showed cancer patients harboring germline CSF1R c.1085A>G genetic variant had better survival. Here, primary tumor samples from a stage III colorectal cancer (CRC) cohort were analyzed by a targeted gene expression assay containing 395 immune-related genes to study the immune mechanism underlying the different outcomes. CRC patients with CSF1R c.1085 genotype A_G had a better disease-free and overall survival than those with CSF1R genotype A_A. Compared to the group of patients without CSF1R variant, higher CD40LG expression, a surface marker of T cells, was found in the tumor tissues of patients with CSF1R c.1085 variant. In parallel with the higher CD40LG gene expression, immunofluorescent staining also showed more CD3+CD40L+ T cell infiltrates in tumors with CSF1R c.1085 genotype A_G. Moreover, higher IL-2 expression, known to be regulated by CD40 pathway, was also observed in tumors with CSF1R c.1085 genotype A_G than genotype A_A. Higher IL-2 expression generated by the interaction of CD40 ligand and CD40 between T cells and macrophages with CSF1R c.1085A>G variant is the potential mechanism explaining the different outcomes.
Collapse
|
6
|
Dhar S, Datta A, Brosh RM. DNA helicases and their roles in cancer. DNA Repair (Amst) 2020; 96:102994. [PMID: 33137625 DOI: 10.1016/j.dnarep.2020.102994] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2020] [Accepted: 09/28/2020] [Indexed: 12/15/2022]
Abstract
DNA helicases, known for their fundamentally important roles in genomic stability, are high profile players in cancer. Not only are there monogenic helicase disorders with a strong disposition to cancer, it is well appreciated that helicase variants are associated with specific cancers (e.g., breast cancer). Flipping the coin, DNA helicases are frequently overexpressed in cancerous tissues and reduction in helicase gene expression results in reduced proliferation and growth capacity, as well as DNA damage induction and apoptosis of cancer cells. The seminal roles of helicases in the DNA damage and replication stress responses, as well as DNA repair pathways, validate their vital importance in cancer biology and suggest their potential values as targets in anti-cancer therapy. In recent years, many laboratories have characterized the specialized roles of helicase to resolve transcription-replication conflicts, maintain telomeres, mediate cell cycle checkpoints, remodel stalled replication forks, and regulate transcription. In vivo models, particularly mice, have been used to interrogate helicase function and serve as a bridge for preclinical studies that may lead to novel therapeutic approaches. In this review, we will summarize our current knowledge of DNA helicases and their roles in cancer, emphasizing the latest developments.
Collapse
Affiliation(s)
- Srijita Dhar
- Laboratory of Molecular Gerontology, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA
| | - Arindam Datta
- Laboratory of Molecular Gerontology, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA
| | - Robert M Brosh
- Laboratory of Molecular Gerontology, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA.
| |
Collapse
|
7
|
Pandith AA, Wani ZA, Qasim I, Afroze D, Manzoor U, Amin I, Baba SM, Koul A, Anwar I, Mohammad F, Bhat AR, Shah P. Association of strong risk of hTERT gene polymorphic variants to malignant glioma and its prognostic implications with respect to different histological types and survival of glioma cases. J Gene Med 2020; 22:e3260. [PMID: 32783258 DOI: 10.1002/jgm.3260] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2020] [Revised: 07/03/2020] [Accepted: 07/31/2020] [Indexed: 12/19/2022] Open
Abstract
BACKGROUND Germline genetic variants of human telomerase reverse transcriptase (hTERT) are known to predispose for various malignancies, including glioma. The present study investigated genetic variation of hTERT T/G (rs2736100) and hTERT G/A (rs2736098) with respect to glioma risk. METHODS Confirmed cases (n = 106) were tested against 210 cancer-free healthy controls by the polymerase chain reaction-restriction fragment length polymorphism technique for genotyping. RESULTS Homozygous variant 'GG' genotype of rs2736100 frequency was > 4-fold significantly different in cases versus controls (39.6% 17.2%; p < 0.0001). Furthermore, variant 'G' allele was found to be significantly associated with cases (0.5 versus 0.2 in controls; p < 0.0001). Homozygous variant rs2736098 'AA' genotype (35.8% versus 23.8%) and allele 'A' (0.49 versus 0.34) showed a marked significant difference in cases and controls, respectively (p < 0.05). In hTERT rs2736100, the GG genotype significantly presented more in higher grades and GBM (p < 0.0001). Furthermore, the GG variant of hTERT rs2736100 had a poor probability with respect to the overall survival of patients compared to TG and TT genotypes (log rank p = 0.03). Interestingly, two haplotypes of hTERT rs2736100/rs2736098 were identified as GG and GA that conferred a > 3- and 5-fold risk to glioma patients respectively, where variant G/A haplotype was observed to have the highest impact with respect to glioma risk (p < 0.0001). CONCLUSIONS The results of the present study indicate that hTERT rs2736098 and rs2736100 variants play an important role in conferring a strong risk of developing glioma. Furthermore, hTERT rs2736100 GG variant appears to play a role in the bad prognosis of glioma patients. Haplotypes GG and GA could prove to be vital tools for monitoring risk in glioma patients.
Collapse
Affiliation(s)
- Arshad A Pandith
- Advanced Centre for Human Genetics, Sher-I-Kashmir Institute of Medical Sciences (SKIMS), Srinagar, Jammu and Kashmir, India
| | - Zahoor A Wani
- Advanced Centre for Human Genetics, Sher-I-Kashmir Institute of Medical Sciences (SKIMS), Srinagar, Jammu and Kashmir, India
| | - Iqbal Qasim
- Advanced Centre for Human Genetics, Sher-I-Kashmir Institute of Medical Sciences (SKIMS), Srinagar, Jammu and Kashmir, India
| | - Dil Afroze
- Advanced Centre for Human Genetics, Sher-I-Kashmir Institute of Medical Sciences (SKIMS), Srinagar, Jammu and Kashmir, India
| | - Usma Manzoor
- Advanced Centre for Human Genetics, Sher-I-Kashmir Institute of Medical Sciences (SKIMS), Srinagar, Jammu and Kashmir, India
| | - Ina Amin
- Advanced Centre for Human Genetics, Sher-I-Kashmir Institute of Medical Sciences (SKIMS), Srinagar, Jammu and Kashmir, India
| | - Shahid M Baba
- Immunology and Molecular Medicine, SKIMS, Srinagar, Jammu and Kashmir, India
| | - Aabid Koul
- Advanced Centre for Human Genetics, Sher-I-Kashmir Institute of Medical Sciences (SKIMS), Srinagar, Jammu and Kashmir, India
| | - Iqra Anwar
- Advanced Centre for Human Genetics, Sher-I-Kashmir Institute of Medical Sciences (SKIMS), Srinagar, Jammu and Kashmir, India
| | - Fozia Mohammad
- Advanced Centre for Human Genetics, Sher-I-Kashmir Institute of Medical Sciences (SKIMS), Srinagar, Jammu and Kashmir, India
| | - Abdul R Bhat
- Department of Neurosurgery, SKIMS, Srinagar, Jammu and Kashmir, India
| | - Parveen Shah
- Department of Pathology, SKIMS, Srinagar, Jammu and Kashmir, India
| |
Collapse
|
8
|
Li H, Yan R, Chen W, Ding X, Liu J, Chen G, Zhao Q, Tang Y, Lv S, Liu S, Yu Y. Long non coding RNA SLC26A4-AS1 exerts antiangiogenic effects in human glioma by upregulating NPTX1 via NFKB1 transcriptional factor. FEBS J 2020; 288:212-228. [PMID: 32255252 DOI: 10.1111/febs.15325] [Citation(s) in RCA: 33] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2019] [Revised: 01/07/2020] [Accepted: 04/01/2020] [Indexed: 12/16/2022]
Abstract
Malignant gliomas are a heterogeneous group of brain tumors with a poor prognosis, which is largely due to its aggressive invasiveness and angiogenesis. In recent years, it has been found that multiple long noncoding RNAs (lncRNAs) participate in a wide range of biological functions including angiogenesis through the regulation of gene expression in cancers. In this study, we investigate and report the novel role of lncRNA SLC26A4-AS1 in gliomas, with a novel mechanism involving transcription factors NFKB1 and NPTX1. We determined that SLC26A4-AS1 was downregulated in human glioma tissues and cells. Furthermore, overexpression of SLC26A4-AS1 or NPTX1 restrained the aggressiveness of glioma cells and their pro-angiogenic ability. SLC26A4-AS1 was also found to upregulate NPTX1 by recruiting NFKB1 into the NPTX1 promoter. Moreover, silencing of either NPTX1 or NFKB1 restored the aggressive and pro-angiogenic properties of glioma cells in the presence of SLC26A4-AS1. Taken together, we demonstrate that SLC26A4-AS1 promotes NPTX1 transcriptional activity by recruiting NFKB1 and thus exerting antiangiogenic effects on glioma cells. This study provides an experimental basis for the intervention of SLC26A4-AS1 in the treatment of gliomas.
Collapse
Affiliation(s)
- Haijun Li
- Department of Neurology, Taizhou Second People's Hospital, China
| | - Raoyu Yan
- Ankang Ward, Taizhou Second People's Hospital, China
| | - Weiqing Chen
- Clinical Laboratory, Taizhou Women and Children Hospital, China
| | - Xiaofei Ding
- Central Laboratory, Taizhou University Medical School, China
| | - Jiaming Liu
- School of Basic Medical Sciences, Wenzhou Medical University, China
| | - Guang Chen
- Central Laboratory, Taizhou University Medical School, China
| | - Qunfeng Zhao
- Blood Transfusion Division, Taizhou Municipal Hospital, China
| | - Yiping Tang
- Blood Transfusion Division, Taizhou Municipal Hospital, China
| | - Siye Lv
- Blood Transfusion Division, Taizhou Municipal Hospital, China
| | - Shuangchun Liu
- Blood Transfusion Division, Taizhou Municipal Hospital, China
| | - Ying Yu
- Infection Medicine, Taizhou Municipal Hospital, China
| |
Collapse
|
9
|
RTEL1 suppresses G-quadruplex-associated R-loops at difficult-to-replicate loci in the human genome. Nat Struct Mol Biol 2020; 27:424-437. [PMID: 32398827 DOI: 10.1038/s41594-020-0408-6] [Citation(s) in RCA: 51] [Impact Index Per Article: 12.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2019] [Accepted: 02/26/2020] [Indexed: 12/14/2022]
Abstract
Oncogene activation during tumorigenesis generates DNA replication stress, a known driver of genome rearrangements. In response to replication stress, certain loci, such as common fragile sites and telomeres, remain under-replicated during interphase and subsequently complete locus duplication in mitosis in a process known as 'MiDAS'. Here, we demonstrate that RTEL1 (regulator of telomere elongation helicase 1) has a genome-wide role in MiDAS at loci prone to form G-quadruplex-associated R-loops, in a process that is dependent on its helicase function. We reveal that SLX4 is required for the timely recruitment of RTEL1 to the affected loci, which in turn facilitates recruitment of other proteins required for MiDAS, including RAD52 and POLD3. Our findings demonstrate that RTEL1 is required for MiDAS and suggest that RTEL1 maintains genome stability by resolving conflicts that can arise between the replication and transcription machineries.
Collapse
|
10
|
Peng L, Ming Y, Zhang L, Zhou J, Xiang W, Zeng S, He H, Chen L. MicroRNA-30a suppresses self-renewal and tumorigenicity of glioma stem cells by blocking the NT5E-dependent Akt signaling pathway. FASEB J 2020; 34:5128-5143. [PMID: 32067282 DOI: 10.1096/fj.201802629rr] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2018] [Revised: 09/10/2019] [Accepted: 09/23/2019] [Indexed: 01/15/2023]
Abstract
Over the past decade, increasing researches have demonstrated the implication of microRNAs (miRNAs or miRs) in tumorigenicity of glioma stem cells (GSCs). The regulatory functions of miRNAs in GSCs have emerged as potential therapeutic candidates for glioma treatment. Herein, we aim to investigate the role of miR-30a in the proliferation and self-renewal of GSCs and the possible mechanism in relation to ecto-5'-nucleotidase (NT5E)-dependent Akt signaling pathway. RT-qPCR and Western blot analysis were performed to determine the expression of miR-30a and NT5E in glioma tissues and cell lines. GSCs were isolated from glioma cells and identified using flow cytometry. The relationship between miR-30a and NT5E was determined by dual-luciferase reporter gene assay. Gain- and loss-of-function experiments were performed to examine the effects of miR-30a and NT5E on sphere formation, colony formation, and proliferation of GSCs in vitro, as well as orthotopic tumor growth of GSCs in nude mice. Additionally, the Akt signaling pathway was blocked with an Akt inhibitor, LY294002, to investigate its involvement in the regulatory effect of miR30a. miR-30a was poorly expressed in glioma tissues and cell lines as well as GSCs. NT5E, highly expressed in GSCs, was identified as a target of miR-30a. In addition, miR-30a upregulation or NT5E silencing could reduce GSC sphere formation, clone formation, proliferation, and orthotopic tumor growth in nude mice. Moreover, miR-30a inhibited the activation of the Akt signaling pathway by targeting NT5E, and ultimately suppressing the self-renewal and orthotopic tumor growth of GSCs. Our results demonstrate that miR-30a targets NT5E to inhibit the Akt signaling pathway, by which could suppress the self-renewal and orthotopic tumor growth of GSCs. Those findings may provide theoretical basis of miR-30a as a therapeutic target to suppress the glioma progression.
Collapse
Affiliation(s)
- Lilei Peng
- Department of Neurosurgery, The Affiliated Hospital of Southwest Medical University, Luzhou, P. R. China.,Neurosurgical Clinical Research Center of Sichuan Province, Luzhou, P. R. China
| | - Yang Ming
- Department of Neurosurgery, The Affiliated Hospital of Southwest Medical University, Luzhou, P. R. China.,Neurosurgical Clinical Research Center of Sichuan Province, Luzhou, P. R. China
| | - Ling Zhang
- Department of Neurosurgery, The Affiliated Hospital of Southwest Medical University, Luzhou, P. R. China.,Neurosurgical Clinical Research Center of Sichuan Province, Luzhou, P. R. China
| | - Jie Zhou
- Department of Neurosurgery, The Affiliated Hospital of Southwest Medical University, Luzhou, P. R. China.,Neurosurgical Clinical Research Center of Sichuan Province, Luzhou, P. R. China
| | - Wei Xiang
- Department of Neurosurgery, The Affiliated Hospital of Southwest Medical University, Luzhou, P. R. China.,Neurosurgical Clinical Research Center of Sichuan Province, Luzhou, P. R. China
| | - Shan Zeng
- Department of Neurosurgery, The Affiliated Hospital of Southwest Medical University, Luzhou, P. R. China.,Neurosurgical Clinical Research Center of Sichuan Province, Luzhou, P. R. China
| | - Haiping He
- Department of Neurosurgery, The Affiliated Hospital of Southwest Medical University, Luzhou, P. R. China.,Neurosurgical Clinical Research Center of Sichuan Province, Luzhou, P. R. China
| | - Ligang Chen
- Department of Neurosurgery, The Affiliated Hospital of Southwest Medical University, Luzhou, P. R. China.,Neurosurgical Clinical Research Center of Sichuan Province, Luzhou, P. R. China
| |
Collapse
|
11
|
Creed JH, Peeri NC, Anic GM, Thompson RC, Olson JJ, LaRocca RV, Chowdhary SA, Brockman JD, Gerke TA, Nabors LB, Egan KM. Methylmercury exposure, genetic variation in metabolic enzymes, and the risk of glioma. Sci Rep 2019; 9:10861. [PMID: 31350461 PMCID: PMC6659774 DOI: 10.1038/s41598-019-47284-4] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2018] [Accepted: 07/15/2019] [Indexed: 12/25/2022] Open
Abstract
Methylmercury (MeHg) is an environmental neurotoxin with human exposure mainly from dietary intake of contaminated fish. Exposure to MeHg has been implicated in neurological damage, but research on its role in cancers, specifically glioma, is limited. In a glioma case-control study, we examined associations between toenail mercury (Hg) and glioma risk. We also examined genetic polymorphisms in 13 genes related to MeHg metabolism for association with glioma risk; genetic associations were also studied in the UK Biobank cohort. Median toenail Hg in cases and controls, respectively, was 0.066 μg/g and 0.069 μg/g (interquartile range (IQR): 0.032-0.161 and 0.031-0.150 μg/g). Toenail Hg was not found to be significantly associated with glioma risk (Odds Ratio: 1.02; 95% Confidence Interval: 0.91, 1.14; p = 0.70 in analysis for ordinal trend with increasing quartile of toenail MeHg). No genetic variant was statistically significant in both of the studies; one variant, rs11859163 (MMP2) had a combined p-value of 0.02 though it was no longer significant after adjustment for multiple testing (Bonferroni corrected p = 1). This study does not support the hypothesis that exposure to MeHg plays a role in the development of glioma at levels of exposure found in this study population.
Collapse
Affiliation(s)
- Jordan H Creed
- Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center & Research Institute, Inc., Tampa, FL, 33612, USA
| | - Noah C Peeri
- Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center & Research Institute, Inc., Tampa, FL, 33612, USA
| | - Gabriella M Anic
- Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center & Research Institute, Inc., Tampa, FL, 33612, USA
| | - Reid C Thompson
- Department of Neurological Surgery, Vanderbilt University Medical Center, Nashville, TN, 37232, USA
| | - Jeffrey J Olson
- Department of Neurosurgery, Emory School of Medicine, Atlanta, GA, 30322, USA
| | | | - Sajeel A Chowdhary
- Neuro-Oncology Program, Lynn Cancer Institute, 701 NW 13th Street, Boca Raton, FL, 33486, USA
| | - John D Brockman
- University of Missouri Research Reactor, University of Missouri, Columbia, MO, 65211, USA
| | - Travis A Gerke
- Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center & Research Institute, Inc., Tampa, FL, 33612, USA
| | - Louis B Nabors
- Neuro-oncology Program, University of Alabama at Birmingham, Birmingham, AL, 35294, USA
| | - Kathleen M Egan
- Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center & Research Institute, Inc., Tampa, FL, 33612, USA.
| |
Collapse
|
12
|
Ostrom QT, Egan KM, Nabors LB, Gerke T, Thompson RC, Olson JJ, LaRocca R, Chowdhary S, Eckel-Passow JE, Armstrong G, Wiencke JK, Bernstein JL, Claus EB, Il'yasova D, Johansen C, Lachance DH, Lai RK, Merrell RT, Olson SH, Sadetzki S, Schildkraut JM, Shete S, Houlston RS, Jenkins RB, Wrensch MR, Melin B, Amos CI, Huse JT, Barnholtz-Sloan JS, Bondy ML. Glioma risk associated with extent of estimated European genetic ancestry in African Americans and Hispanics. Int J Cancer 2019; 146:739-748. [PMID: 30963577 DOI: 10.1002/ijc.32318] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2018] [Revised: 01/30/2019] [Accepted: 02/14/2019] [Indexed: 12/15/2022]
Abstract
Glioma incidence is highest in non-Hispanic Whites, and to date, glioma genome-wide association studies (GWAS) to date have only included European ancestry (EA) populations. African Americans and Hispanics in the US have varying proportions of EA, African (AA) and Native American ancestries (NAA). It is unknown if identified GWAS loci or increased EA is associated with increased glioma risk. We assessed whether EA was associated with glioma in African Americans and Hispanics. Data were obtained for 832 cases and 675 controls from the Glioma International Case-Control Study and GliomaSE Case-Control Study previously estimated to have <80% EA, or self-identify as non-White. We estimated global and local ancestry using fastStructure and RFMix, respectively, using 1,000 genomes project reference populations. Within groups with ≥40% AA (AFR≥0.4 ), and ≥15% NAA (AMR≥0.15 ), genome-wide association between local EA and glioma was evaluated using logistic regression conditioned on global EA for all gliomas. We identified two regions (7q21.11, p = 6.36 × 10-4 ; 11p11.12, p = 7.0 × 10-4 ) associated with increased EA, and one associated with decreased EA (20p12.13, p = 0.0026) in AFR≥0.4 . In addition, we identified a peak at rs1620291 (p = 4.36 × 10-6 ) in 7q21.3. Among AMR≥0.15 , we found an association between increased EA in one region (12q24.21, p = 8.38 × 10-4 ), and decreased EA in two regions (8q24.21, p = 0. 0010; 20q13.33, p = 6.36 × 10-4 ). No other significant associations were identified. This analysis identified an association between glioma and two regions previously identified in EA populations (8q24.21, 20q13.33) and four novel regions (7q21.11, 11p11.12, 12q24.21 and 20p12.13). The identifications of novel association with EA suggest regions to target for future genetic association studies.
Collapse
Affiliation(s)
- Quinn T Ostrom
- Department of Medicine, Section of Epidemiology and Population Sciences, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX
| | - Kathleen M Egan
- Division of Population Sciences, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
| | - L Burt Nabors
- Neuro-Oncology Program, University of Alabama at Birmingham, Birmingham, AL
| | - Travis Gerke
- Division of Population Sciences, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
| | - Reid C Thompson
- Department of Neurological Surgery, Vanderbilt University Medical Center, Nashville, TN
| | - Jeffrey J Olson
- Department of Neurosurgery, Emory University School of Medicine, Atlanta, GA
| | - Renato LaRocca
- Department of Hematology-Oncology, Norton Cancer Institute, Louisville, KY
| | | | - Jeanette E Eckel-Passow
- Division of Biomedical Statistics and Informatics, Mayo Clinic College of Medicine, Rochester, MN
| | - Georgina Armstrong
- Department of Medicine, Section of Epidemiology and Population Sciences, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX
| | - John K Wiencke
- Department of Neurological Surgery, School of Medicine, University of California, San Francisco, San Francisco, CA
| | - Jonine L Bernstein
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, NY, New York
| | - Elizabeth B Claus
- School of Public Health, Yale University, New Haven, CT.,Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA
| | - Dora Il'yasova
- Department of Epidemiology and Biostatistics, School of Public Health, Georgia State University, Atlanta, GA.,Cancer Control and Prevention Program, Department of Community and Family Medicine, Duke University Medical Center, Durham, NC.,Duke Cancer Institute, Duke University Medical Center, Durham, NC
| | - Christoffer Johansen
- Oncology Clinic, Finsen Center, Rigshospitalet and Survivorship Research Unit, The Danish Cancer Society Research Center, Copenhagen, Denmark
| | - Daniel H Lachance
- Department of Neurology, Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Rochester, MN
| | - Rose K Lai
- Department of Neurology and Preventive Medicine, Keck School of Medicine, University of Southern California, CA, Los Angeles
| | - Ryan T Merrell
- Department of Neurology, NorthShore University HealthSystem, Evanston, IL
| | - Sara H Olson
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, NY, New York
| | - Siegal Sadetzki
- Cancer and Radiation Epidemiology Unit, Gertner Institute, Chaim Sheba Medical Center, Tel Hashomer, Israel.,Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
| | - Joellen M Schildkraut
- Department of Public Health Sciences, University of Virginia School of Medicine, Charlottesville, VA
| | - Sanjay Shete
- Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX
| | - Richard S Houlston
- Division of Genetics and Epidemiology, The Institute of Cancer Research in Sutton, Surrey, United Kingdom
| | - Robert B Jenkins
- Department of Laboratory Medicine and Pathology, Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Rochester, MN
| | - Margaret R Wrensch
- Department of Neurological Surgery, School of Medicine, University of California, San Francisco, San Francisco, CA
| | - Beatrice Melin
- Department of Radiation Sciences, Umeå University, Umeå, Sweden
| | - Christopher I Amos
- Institute for Clinical and Translational Research, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX
| | - Jason T Huse
- Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX
| | - Jill S Barnholtz-Sloan
- Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH
| | - Melissa L Bondy
- Department of Medicine, Section of Epidemiology and Population Sciences, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX
| |
Collapse
|
13
|
González-Castro TB, Juárez-Rojop IE, López-Narváez ML, Tovilla-Zárate CA, Genis-Mendoza AD, Pérez-Hernández N, Martínez-Magaña JJ, Rodríguez-Pérez JM. Genetic Polymorphisms of CCDC26 rs891835, rs6470745, and rs55705857 in Glioma Risk: A Systematic Review and Meta-analysis. Biochem Genet 2019; 57:583-605. [DOI: 10.1007/s10528-019-09911-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2018] [Accepted: 02/07/2019] [Indexed: 01/03/2023]
|
14
|
Karami F, Salahshourifar I, Houshmand M. The Study of rs693 and rs515135 in APOB in People with Familial Hypercholestrolemia. CELL JOURNAL 2018; 21:86-91. [PMID: 30507093 PMCID: PMC6275425 DOI: 10.22074/cellj.2019.5692] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/04/2018] [Accepted: 06/03/2018] [Indexed: 11/04/2022]
Abstract
Objective APOB-related familial hypercholesterolemia (FH) is the most common hereditary hyperchlosterolemia with
an autosomal dominant pattern. A number of APOB variants are the most important risk factors for hyperchlosterolemia.
APOB is a large glycoprotein that plays an important role in the metabolism of lipoproteins in the human body. Small
changes in the structure and function of APOB can cause major problems in lipid metabolism. Two forms of APOB are
produced by an editing process of gene replication. APOB48 is required for the production of chylomicrons in the small
intestine and APOB100 is essential in liver for the production of very low density lipoprotein (VLDL) and is also a ligand
for LDL receptor (LDLR) that mediates LDL endocytosis.
Materials and Methods In this case-control study, rs693 (in exon 26 of APOB) and rs515135 (5 'end of APOB) single
nucleotide polymorphisms (SNPs) were analyzed in 120 cases of familial hypercholesterolemia and 120 controls. Both
SNPs were genotyped by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) where
PCR products were digested with specific restriction enzymes recognising each single nucleotide polymorphism.
Results This study was analyzed by odds-ratio (OR) and its 95% confidence interval (CI) to examine the association of
the two SNPs with familial hypercholostermia susceptibility. Statistical analysis showed that both SNPs were in Hardy-
Weinberg equilibrium.
Conclusion We found no significant relationship between rs515135 and familiar hypercholesterolemia. However,
there was a significant association between the C allele of rs693 and high familial cholesterol levels. Furthermore, it
seems the dominant model of T allele occurrence has a protective role in emergence of disease.
Collapse
Affiliation(s)
- Fatemeh Karami
- Department of Biology, Science Faculty, Science and Research Branch, Islamic Azad University, Tehran, Iran
| | - Iman Salahshourifar
- Department of Biology, Science Faculty, Science and Research Branch, Islamic Azad University, Tehran, Iran
| | - Masoud Houshmand
- Department of Medical Genetics, National Institute for Genetic Engineering and Biotechnology, Tehran, Iran. Electronic Address:
| |
Collapse
|
15
|
Namgoong S, Cheong HS, Kim JH, Kim LH, Seo JY, Kang SG, Yoon SJ, Kim SH, Chang JH, Shin HD. Association analysis of RTEL1 variants with risk of adult gliomas in a Korean population. PLoS One 2018; 13:e0207660. [PMID: 30462709 PMCID: PMC6248978 DOI: 10.1371/journal.pone.0207660] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2018] [Accepted: 11/04/2018] [Indexed: 01/28/2023] Open
Abstract
Previous studies have identified multiple loci for inherited susceptibility to glioma development, including the regulator of telomere elongation helicase 1 (RTEL1). However, the association between RTEL1 variants and risk of glioma has not been well understood. Therefore, we sought to comprehensively examine the genetic interaction between RTEL1 variants and risk of glioma with respect to defined histological and molecular subtypes. We employed a case-control study involving 250 adult glioma patients with previous molecular alterations and 375 population–based controls within Korean populations. Statistical analyses on the association between RTEL1 single nucleotide polymorphisms (SNPs) and glioma risk were conducted using unconditional logistic regression. Additional conditional and stepwise analyses were performed on significant RTEL1 SNPs. We detected significant associations (Bonferroni P < .05) between six SNPs (rs6089953, rs3848669, rs6010620, rs3787089, rs6062302, and rs115303435) and risk of glioma in the Korean subjects. The two coding variants, rs6062302 (D664D) and rs115303435 (A1059T), were plausibly causal variants and were independent among the significantly associated RTEL1 variants. The glioma subgroup analyses showed that the causal variants (rs6062302 and rs115303435) may be associated with increased risk of glioma regardless of histological grades and molecular alterations. This study provides a deeper understanding of relationships between RTEL1 variants and risk of glioma. Further studies are required to ascertain the impact of those variants on glioma susceptibility.
Collapse
Affiliation(s)
- Suhg Namgoong
- Department of Life Science, Sogang University, Seoul, Republic of Korea
| | - Hyun Sub Cheong
- Department of Genetic Epidemiology, SNP Genetics Inc., Seoul, Republic of Korea
| | - Jeong-Hyun Kim
- Asan Institute for Life Sciences, University of Ulsan Collage of Medicine, Seoul, Republic of Korea
| | - Lyoung Hyo Kim
- Department of Genetic Epidemiology, SNP Genetics Inc., Seoul, Republic of Korea
| | - Jung Yeon Seo
- Department of Life Science, Sogang University, Seoul, Republic of Korea
| | - Seok-Gu Kang
- Department of Neurosurgery, Yonsei University College of Medicine, Seoul, Republic of Korea
| | - Seon-Jin Yoon
- Department of Neurosurgery, Yonsei University College of Medicine, Seoul, Republic of Korea
- Department of Biochemistry and Molecular Biology, College of Medicine, Yonsei University, Seoul, Republic of Korea
| | - Se Hoon Kim
- Department of Pathology, Yonsei University College of Medicine, Seoul, Republic of Korea
| | - Jong Hee Chang
- Department of Neurosurgery, Yonsei University College of Medicine, Seoul, Republic of Korea
- * E-mail: (HDS); (JHC)
| | - Hyoung Doo Shin
- Department of Life Science, Sogang University, Seoul, Republic of Korea
- Research Institute for Basic Science, Sogang University, Seoul, Republic of Korea
- * E-mail: (HDS); (JHC)
| |
Collapse
|
16
|
Peeri NC, Creed JH, Anic GM, Thompson RC, Olson JJ, LaRocca RV, Chowdhary SA, Brockman JD, Gerke TA, Nabors LB, Egan KM. Toenail selenium, genetic variation in selenoenzymes and risk and outcome in glioma. Cancer Epidemiol 2018; 55:45-51. [PMID: 29777993 DOI: 10.1016/j.canep.2018.05.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2018] [Revised: 05/02/2018] [Accepted: 05/03/2018] [Indexed: 11/24/2022]
Abstract
BACKGROUND Selenium is an essential trace element obtained through diet that plays a critical role in DNA synthesis and protection from oxidative damage. Selenium intake and polymorphisms in selenoproteins have been linked to the risk of certain cancers though data for glioma are sparse. METHODS In a case-control study of glioma, we examined the associations of selenium in toenails and genetic variants in the selenoenzyme pathway with the risk of glioma and patient survival. A total of 423 genetic variants in 29 candidate genes in the selenoenzyme pathway were studied in 1547 glioma cases and 1014 healthy controls. Genetic associations were also examined in the UK Biobank cohort comprised of 313,868 persons with 322 incident glioma cases. Toenail selenium was measured in a subcohort of 300 glioma cases and 300 age-matched controls from the case-control study. RESULTS None of the 423 variants studied were consistently associated with glioma risk in the case-control and cohort studies. Moreover, toenail selenium in the case-control study had no significant association with glioma risk (p trend = 0.70) or patient survival among 254 patients with high grade tumors (p trend = 0.70). CONCLUSION The present study offers no support for the hypothesis that selenium plays a role in the onset of glioma or patient outcome.
Collapse
Affiliation(s)
- Noah C Peeri
- Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center & Research Institute, Tampa FL, 33612, USA
| | - Jordan H Creed
- Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center & Research Institute, Tampa FL, 33612, USA
| | - Gabriella M Anic
- Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center & Research Institute, Tampa FL, 33612, USA
| | - Reid C Thompson
- Department of Neurological Surgery, Vanderbilt University Medical Center, Nashville, TN 37232, USA
| | - Jeffrey J Olson
- Department of Neurosurgery, Emory School of Medicine, Atlanta, GA 30322, USA
| | | | - Sajeel A Chowdhary
- Neuro-Oncology Program, Lynn Cancer Institute, 701 NW 13th Street, Boca Raton, FL 33486, USA
| | - John D Brockman
- University of Missouri Research Reactor, University of Missouri, Columbia, MO 65211, USA
| | - Travis A Gerke
- Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center & Research Institute, Tampa FL, 33612, USA
| | - L Burton Nabors
- Neuro-oncology Program, University of Alabama at Birmingham, Birmingham, AL 35294, USA
| | - Kathleen M Egan
- Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center & Research Institute, Tampa FL, 33612, USA.
| |
Collapse
|
17
|
Gaspar TB, Sá A, Lopes JM, Sobrinho-Simões M, Soares P, Vinagre J. Telomere Maintenance Mechanisms in Cancer. Genes (Basel) 2018; 9:E241. [PMID: 29751586 PMCID: PMC5977181 DOI: 10.3390/genes9050241] [Citation(s) in RCA: 77] [Impact Index Per Article: 12.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2018] [Revised: 04/20/2018] [Accepted: 04/23/2018] [Indexed: 12/12/2022] Open
Abstract
Tumour cells can adopt telomere maintenance mechanisms (TMMs) to avoid telomere shortening, an inevitable process due to successive cell divisions. In most tumour cells, telomere length (TL) is maintained by reactivation of telomerase, while a small part acquires immortality through the telomerase-independent alternative lengthening of telomeres (ALT) mechanism. In the last years, a great amount of data was generated, and different TMMs were reported and explained in detail, benefiting from genome-scale studies of major importance. In this review, we address seven different TMMs in tumour cells: mutations of the TERT promoter (TERTp), amplification of the genes TERT and TERC, polymorphic variants of the TERT gene and of its promoter, rearrangements of the TERT gene, epigenetic changes, ALT, and non-defined TMM (NDTMM). We gathered information from over fifty thousand patients reported in 288 papers in the last years. This wide data collection enabled us to portray, by organ/system and histotypes, the prevalence of TERTp mutations, TERT and TERC amplifications, and ALT in human tumours. Based on this information, we discuss the putative future clinical impact of the aforementioned mechanisms on the malignant transformation process in different setups, and provide insights for screening, prognosis, and patient management stratification.
Collapse
Affiliation(s)
- Tiago Bordeira Gaspar
- Cancer Signaling and Metabolism Group, Institute for Research and Innovation in Health Sciences (i3S), University of Porto, 4200-135 Porto, Portugal.
- Cancer Signaling and Metabolism Group, Institute of Molecular Pathology and Immunology of the University of Porto (Ipatimup), 4200-135 Porto, Portugal.
- Medical Faculty of University of Porto (FMUP), 4200-139 Porto, Portugal.
- Abel Salazar Biomedical Sciences Institute (ICBAS), University of Porto, 4050-313 Porto, Portugal.
| | - Ana Sá
- Cancer Signaling and Metabolism Group, Institute for Research and Innovation in Health Sciences (i3S), University of Porto, 4200-135 Porto, Portugal.
- Cancer Signaling and Metabolism Group, Institute of Molecular Pathology and Immunology of the University of Porto (Ipatimup), 4200-135 Porto, Portugal.
- Abel Salazar Biomedical Sciences Institute (ICBAS), University of Porto, 4050-313 Porto, Portugal.
| | - José Manuel Lopes
- Cancer Signaling and Metabolism Group, Institute for Research and Innovation in Health Sciences (i3S), University of Porto, 4200-135 Porto, Portugal.
- Cancer Signaling and Metabolism Group, Institute of Molecular Pathology and Immunology of the University of Porto (Ipatimup), 4200-135 Porto, Portugal.
- Medical Faculty of University of Porto (FMUP), 4200-139 Porto, Portugal.
- Department of Pathology and Oncology, Centro Hospitalar São João, 4200-139 Porto, Portugal.
| | - Manuel Sobrinho-Simões
- Cancer Signaling and Metabolism Group, Institute for Research and Innovation in Health Sciences (i3S), University of Porto, 4200-135 Porto, Portugal.
- Cancer Signaling and Metabolism Group, Institute of Molecular Pathology and Immunology of the University of Porto (Ipatimup), 4200-135 Porto, Portugal.
- Medical Faculty of University of Porto (FMUP), 4200-139 Porto, Portugal.
- Department of Pathology and Oncology, Centro Hospitalar São João, 4200-139 Porto, Portugal.
| | - Paula Soares
- Cancer Signaling and Metabolism Group, Institute for Research and Innovation in Health Sciences (i3S), University of Porto, 4200-135 Porto, Portugal.
- Cancer Signaling and Metabolism Group, Institute of Molecular Pathology and Immunology of the University of Porto (Ipatimup), 4200-135 Porto, Portugal.
- Abel Salazar Biomedical Sciences Institute (ICBAS), University of Porto, 4050-313 Porto, Portugal.
| | - João Vinagre
- Cancer Signaling and Metabolism Group, Institute for Research and Innovation in Health Sciences (i3S), University of Porto, 4200-135 Porto, Portugal.
- Cancer Signaling and Metabolism Group, Institute of Molecular Pathology and Immunology of the University of Porto (Ipatimup), 4200-135 Porto, Portugal.
- Medical Faculty of University of Porto (FMUP), 4200-139 Porto, Portugal.
| |
Collapse
|
18
|
Mikhailova V, Gulaia V, Tiasto V, Rybtsov S, Yatsunskaya M, Kagansky A. Towards an advanced cell-based in vitro glioma model system. AIMS GENETICS 2018; 5:91-112. [PMID: 31435515 PMCID: PMC6698577 DOI: 10.3934/genet.2018.2.91] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 12/09/2017] [Accepted: 03/14/2018] [Indexed: 02/06/2023]
Abstract
The modulation of tumor growth and development in vitro has always been one of the key factors in the research of the malignant transformation, including gliomas, prevalent and most deadly cancers of the brain. Indeed, cellular and molecular biology research employing in vitro model cell-based systems have great potential to advance both the mechanistic understanding and the treatment of human glial tumors, as it facilitates not only the understanding of glioma biology and its regulatory mechanisms Additionally they promise to afford the screening of the putative anti-tumor agents and alternative treatment approaches in a personalized manner, i.e. by virtue of using the patient-derived tumor material for such tests. However, in order to become reliable and representative, glioma model systems need to move towards including most inherent cancer features such as local hypoxia, specific genetic aberrations, native tumor microenvironment, and the three-dimensional extracellular matrix. This review starts with a brief introduction on the general epidemiological and molecular characteristics of gliomas followed by an overview of the cell-based in vitro models currently used in glioma research. As a conclusion, we suggest approaches to move to innovative cell-based in vitro glioma models. We consider that main criteria for selecting these approaches should include the adequate resemblance to the key in vivo characteristics, robustness, cost-effectiveness and ease to use, as well as the amenability to high throughput handling to allow the standardized drug screening.
Collapse
Affiliation(s)
- Valeriia Mikhailova
- Center for Genomic and Regenerative Medicine, School of Biomedicine, Far Eastern Federal University, Vladivostok, Russian Federation
| | - Valeriia Gulaia
- Center for Genomic and Regenerative Medicine, School of Biomedicine, Far Eastern Federal University, Vladivostok, Russian Federation
| | - Vladlena Tiasto
- Center for Genomic and Regenerative Medicine, School of Biomedicine, Far Eastern Federal University, Vladivostok, Russian Federation
| | - Stanislav Rybtsov
- Scottish Centre for Regenerative Medicine of the University of Edinburgh, Edinburgh, United Kingdom
| | - Margarita Yatsunskaya
- Federal Scientific Center of the East Asia Terrestrial Biodiversity FEB RAS 159, Stoletij Vladivostoku Avenue, 690022, Vladivostok, Russian Federation
| | - Alexander Kagansky
- Center for Genomic and Regenerative Medicine, School of Biomedicine, Far Eastern Federal University, Vladivostok, Russian Federation
| |
Collapse
|
19
|
Snetselaar R, van Oosterhout MFM, Grutters JC, van Moorsel CHM. Telomerase Reverse Transcriptase Polymorphism rs2736100: A Balancing Act between Cancer and Non-Cancer Disease, a Meta-Analysis. Front Med (Lausanne) 2018. [PMID: 29536006 PMCID: PMC5835035 DOI: 10.3389/fmed.2018.00041] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
The enzyme telomerase reverse transcriptase (TERT) is essential for telomere maintenance. In replicating cells, maintenance of telomere length is important for the preservation of vital genetic information and prevention of genomic instability. A common genetic variant in TERT, rs2736100 C/A, is associated with both telomere length and multiple diseases. Carriage of the C allele is associated with longer telomere length, while carriage of the A allele is associated with shorter telomere length. Furthermore, some diseases have a positive association with the C and some with the A allele. In this study, meta-analyses were performed for two groups of diseases, cancerous diseases, e.g., lung cancer and non-cancerous diseases, e.g., pulmonary fibrosis, using data from genome-wide association studies and case-control studies. In the meta-analysis it was found that cancer positively associated with the C allele (pooled OR 1.16 [95% CI 1.09–1.23]) and non-cancerous diseases negatively associated with the C allele (pooled OR 0.81 [95% CI 0.65–0.99]). This observation illustrates that the ambiguous role of telomere maintenance in disease hinges, at least in part, on a single locus in telomerase genes. The dual role of this single nucleotide polymorphism also emphasizes that therapeutic agents aimed at influencing telomere maintenance should be used with caution.
Collapse
Affiliation(s)
- Reinier Snetselaar
- Interstitial Lung Diseases Center of Excellence, Department of Pulmonology, St Antonius Hospital, Nieuwegein, Netherlands
| | - Matthijs F M van Oosterhout
- Interstitial Lung Diseases Center of Excellence, Department of Pathology, St Antonius Hospital, Nieuwegein, Netherlands
| | - Jan C Grutters
- Interstitial Lung Diseases Center of Excellence, Department of Pulmonology, St Antonius Hospital, Nieuwegein, Netherlands.,Division of Heart and Lung, University Medical Center Utrecht, Utrecht, Netherlands
| | - Coline H M van Moorsel
- Interstitial Lung Diseases Center of Excellence, Department of Pulmonology, St Antonius Hospital, Nieuwegein, Netherlands.,Division of Heart and Lung, University Medical Center Utrecht, Utrecht, Netherlands
| |
Collapse
|
20
|
Niu F, Li J, Li J, Yan M, Shi X, Jin T. Polymorphisms of telomere-length related genes in three China ethnic groups. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY 2017; 10:9654-9665. [PMID: 31966846 PMCID: PMC6965982] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Received: 06/24/2017] [Accepted: 06/26/2017] [Indexed: 06/10/2023]
Abstract
Little is known about polymorphic distribution of telomere-length related genes among ethnicities, which play important roles in the progression of high-altitude pulmonary edema (HAPE). We genotyped 45 single nucleotide polymorphism (SNP) in 300 unrelated healthy volunteers from the following three Chinese ethnic populations: Han (n = 100), Tibetan (n = 100) and Sherpa (n = 100). We used χ2 test, pairwise FST values, and structure clustering analyses to investigate the genetic differences between these populations. Our results first indicated that rs12615793 (ACYP2), rs10936599 (TERC), rs10069690 (TERT) and rs6010620, rs4809324 (RTEL1) showed the greatest number of significant differences between Han and Tibetan, Sherpa and 11 HapMap populations. Meanwhile, we found that rs1056654 and rs1056629 (MPHOSPH6), rs2320615 (NAF1), rs6010621 (RTEL1), rs8105767 and rs2188972 (ZNF208) genotype frequencies showed considerable divergence among Tibetan and Sherpa. Besides, pairwise FST values and structure clustering analyses revealed that Han exhibited a close genetic affinity with CHD and CHB, but revealed a great genetic heterogeneity with YRI and MKK. This work greatly expanded our understanding of the distribution of telomere-length related genes in Chinese populations and may be helpful to forensic applications and population genetic studies.
Collapse
Affiliation(s)
- Fanglin Niu
- Key Laboratory of Resource Biology and Biotechnology in Western China (Northwest University), Ministry of Education, School of Life Sciences, Northwest UniversityXi’an, Shaanxi, China
| | - Jingjie Li
- Key Laboratory of Resource Biology and Biotechnology in Western China (Northwest University), Ministry of Education, School of Life Sciences, Northwest UniversityXi’an, Shaanxi, China
| | - Jing Li
- Key Laboratory of Resource Biology and Biotechnology in Western China (Northwest University), Ministry of Education, School of Life Sciences, Northwest UniversityXi’an, Shaanxi, China
| | - Mengdan Yan
- Key Laboratory of Resource Biology and Biotechnology in Western China (Northwest University), Ministry of Education, School of Life Sciences, Northwest UniversityXi’an, Shaanxi, China
| | - Xugang Shi
- Xi’an Tianqin Precision Medical InstituteXi’an, Shaanxi, China
| | - Tianbo Jin
- Key Laboratory of Resource Biology and Biotechnology in Western China (Northwest University), Ministry of Education, School of Life Sciences, Northwest UniversityXi’an, Shaanxi, China
- Xi’an Tianqin Precision Medical InstituteXi’an, Shaanxi, China
| |
Collapse
|
21
|
Zanovello WG, Malheiros SMF, Stavale JN, Lanzoni OP, Canteras MM, Santos AJ, Slaviero F, Fernandes B, Cavalheiro S, Paiva Neto MAD. Performance of adjuvant treatment correlates with survival in reoperated glioblastomas. ARQUIVOS DE NEURO-PSIQUIATRIA 2016; 74:887-894. [DOI: 10.1590/0004-282x20160144] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/04/2016] [Accepted: 08/09/2016] [Indexed: 11/21/2022]
Abstract
ABSTRACT Objective To analyze cases of recurrent glioblastoma subjected to reoperation at a Brazilian public healthcare service. Methods A total of 39 patients subjected to reoperation for recurrent glioblastoma at the Department of Neurosurgery, São Paulo Hospital, Federal University of São Paulo, from January 2000 to December 2013 were retrospectively analyzed. Results The median overall survival was 20 months (95% confidence interval – CI = 14.9–25.2), and the median survival after reoperation was 9.1 months (95%CI: 2.8–15.4). The performance of adjuvant treatment after the first operation was the single factor associated with overall survival on multivariate analysis (relative risk – RR = 0.3; 95%CI = 0.2–0.7); p = 0.005). Conclusion The length of survival of patients subjected to reoperation for glioblastoma at a Brazilian public healthcare service was similar to the length reported in the literature. Reoperation should be considered as a therapeutic option for selected patients.
Collapse
|
22
|
TERT promoter mutations and polymorphisms as prognostic factors in primary glioblastoma. Oncotarget 2016; 6:16663-73. [PMID: 26143636 PMCID: PMC4599297 DOI: 10.18632/oncotarget.4389] [Citation(s) in RCA: 86] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2015] [Accepted: 06/12/2015] [Indexed: 01/16/2023] Open
Abstract
Telomerase reverse transcriptase (TERT) activity is up-regulated in several types of tumors including glioblastoma (GBM). In the present study, 128 primary glioblastoma patients were examined for single nucleotide polymorphisms of TERT in blood and in 92 cases for TERT promoter mutations in tumors. TERT promoter mutations were observed in 86% of the tumors and of these, C228T (-124 bp upstream start codon) was detected in 75% and C250T (-146 bp) in 25% of cases. TERT promoter mutations were associated with shorter overall survival (11 vs. 20 months p = 0.002 and 12 vs. 20, p = 0.04 for C228T and C250T, respectively). The minor alleles of rs2736100 and rs10069690 SNP's, located in intron 2 and the promotor regions, respectively, were associated with an increased risk of developing GBM (p = 0.004 and 0.001). GBM patients having both TERT promoter mutations and being homozygous carriers of the rs2853669 C-allele displayed significantly shorter overall survival than those with the wild type allele. The rs2853669 SNP is located in a putative Ets2 binding site in the promoter (-246 bp upstream start codon) close to the C228T and C250T mutation hot spots. Interleukin-6 (IL-6) expression regulated by TERT promoter status and polymorphism, what leads us to think that TERT and IL-6 plays a significant role in GBM, where specific SNPs increase the risk of developing GBM while the rs2853669 SNP and specific mutations in the TERT promoter of the tumor lead to shorter survival.
Collapse
|
23
|
Yuan Y, Qi C, Maling G, Xiang W, Yanhui L, Ruofei L, Yunhe M, Jiewen L, Qing M. TERT mutation in glioma: Frequency, prognosis and risk. J Clin Neurosci 2016; 26:57-62. [DOI: 10.1016/j.jocn.2015.05.066] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2015] [Revised: 05/17/2015] [Accepted: 05/22/2015] [Indexed: 10/22/2022]
|
24
|
Zhang C, Lu Y, Zhang X, Yang D, Shang S, Liu D, Jiang K, Huang W. The role of the RTEL1 rs2297440 polymorphism in the risk of glioma development: a meta-analysis. Neurol Sci 2016; 37:1023-31. [PMID: 26939676 DOI: 10.1007/s10072-016-2531-z] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2015] [Accepted: 02/22/2016] [Indexed: 10/22/2022]
Abstract
The regulator of the telomere elongation helicase1 (RTEL1) gene plays a crucial role in the DNA double-stand break-repair pathway by maintaining genomic stability. Recent epidemiological studies showed that the rs2297440 polymorphism in the RTEL1 gene was a potential risk locus for glioma development, but the results were inconclusive. To clarify the association between this polymorphism and the risk of glioma, we performed a comprehensive meta-analysis. The PubMed, EMBASE, Web of Science, and China National Knowledge Infrastructure databases were systematically searched to identify all relevant published studies up to 30 August 2015. Four eligible studies were finally included. The pooled results indicated that the RTEL1 rs2297440 polymorphism moderately increased the risk of glioma in all genetic models. A comparison of the dominant model CT + CC versus TT (OR 1.40; 95 % CI 1.24-1.60; p < 0.001) indicated that having the C allele conferred a 40 % increased risk of developing glioma. In a subgroup analysis based on geographic location (Europe, Asia, and America), there was an association between the rs2297440 polymorphism and the risk of glioma in all three areas. The results of the subgroup analysis based on source of control indicated an elevated risk of glioma in population-based control studies. This meta-analysis demonstrates that the RTEL1 rs2297440 polymorphism plays a moderate, but significant role in the risk of glioma. Further studies with larger sample sizes are necessary to confirm this finding.
Collapse
Affiliation(s)
- Cuiping Zhang
- Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University, Guangxi Zhuang Autonomous Region, Nanning, 530021, China
| | - Yu Lu
- Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University, Guangxi Zhuang Autonomous Region, Nanning, 530021, China
| | - Xiaolian Zhang
- Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University, Guangxi Zhuang Autonomous Region, Nanning, 530021, China
| | - Dongmei Yang
- Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University, Guangxi Zhuang Autonomous Region, Nanning, 530021, China
| | - Shuxin Shang
- Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University, Guangxi Zhuang Autonomous Region, Nanning, 530021, China
| | - Denghe Liu
- Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University, Guangxi Zhuang Autonomous Region, Nanning, 530021, China
| | - Kongmei Jiang
- Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University, Guangxi Zhuang Autonomous Region, Nanning, 530021, China
| | - Weiqiang Huang
- Department of Geriatric Cardiology, First Affiliated Hospital of Guangxi Medical University, Guangxi, Nanning, 530021, China.
| |
Collapse
|
25
|
Amirian ES, Armstrong GN, Zhou R, Lau CC, Claus EB, Barnholtz-Sloan JS, Il'yasova D, Schildkraut J, Ali-Osman F, Sadetzki S, Johansen C, Houlston RS, Jenkins RB, Lachance D, Olson SH, Bernstein JL, Merrell RT, Wrensch MR, Davis FG, Lai R, Shete S, Amos CI, Scheurer ME, Aldape K, Alafuzoff I, Brännström T, Broholm H, Collins P, Giannini C, Rosenblum M, Tihan T, Melin BS, Bondy ML. The Glioma International Case-Control Study: A Report From the Genetic Epidemiology of Glioma International Consortium. Am J Epidemiol 2016; 183:85-91. [PMID: 26656478 DOI: 10.1093/aje/kwv235] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2015] [Accepted: 06/03/2015] [Indexed: 12/17/2022] Open
Abstract
Decades of research have established only a few etiological factors for glioma, which is a rare and highly fatal brain cancer. Common methodological challenges among glioma studies include small sample sizes, heterogeneity of tumor subtypes, and retrospective exposure assessment. Here, we briefly describe the Glioma International Case-Control (GICC) Study (recruitment, 2010-2013), a study being conducted by the Genetic Epidemiology of Glioma International Consortium that integrates data from multiple data collection sites, uses a common protocol and questionnaire, and includes biospecimen collection. To our knowledge, the GICC Study is the largest glioma study to date that includes collection of blood samples, which will allow for genetic analysis and interrogation of gene-environment interactions.
Collapse
|
26
|
Baskin R, Woods NT, Mendoza-Fandiño G, Forsyth P, Egan KM, Monteiro ANA. Functional analysis of the 11q23.3 glioma susceptibility locus implicates PHLDB1 and DDX6 in glioma susceptibility. Sci Rep 2015; 5:17367. [PMID: 26610392 PMCID: PMC4661592 DOI: 10.1038/srep17367] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2015] [Accepted: 10/28/2015] [Indexed: 12/04/2022] Open
Abstract
Glioma is the most common malignant primary brain tumor and is associated with poor prognosis. Genetic factors contributing to glioma risk have recently been investigated through genome-wide association studies (GWAS), implicating seven independent glioma risk loci in six chromosomal regions. Here, we performed an in-depth functional analysis of the risk locus proximal to the PHLDB1 gene on 11q23.3. We retrieved all SNPs in linkage disequilibrium (r2 ≥ 0.2) with the glioma-associated SNP (rs498872) and performed a comprehensive bioinformatics and experimental functional analysis for the region. After testing candidate SNPs for allele-specific activity in a luciferase-based enhancer scanning assay, we established a subset of 10 functional SNPs in the promoters of PHLDB1 and DDX6, and in a putative enhancer element. Chromatin conformation capture (3C) identified a physical interaction between the enhancer element containing a functional SNP (rs73001406) and the promoter of the DDX6 gene. Knockdown experiments in cell culture and 3D assays to evaluate the role of PHLDB1 and DDX6 suggest that both genes may contribute to the phenotype. These studies reveal the functional landscape of the 11q23.3 glioma susceptibility locus and identify a network of functional SNPs in regulatory elements and two target genes as a possible mechanism driving glioma risk association.
Collapse
Affiliation(s)
- Rebekah Baskin
- Cancer Epidemiology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
| | - Nicholas T Woods
- Cancer Epidemiology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.,Eppley Institute for Research in Cancer, University of Nebraska Medical Center, Omaha, NE 68198, USA
| | - Gustavo Mendoza-Fandiño
- Cancer Epidemiology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
| | - Peter Forsyth
- Department of Neuro-oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
| | - Kathleen M Egan
- Cancer Epidemiology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
| | - Alvaro N A Monteiro
- Cancer Epidemiology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
| |
Collapse
|
27
|
Qi X, Wan Y, Zhan Q, Yang S, Wang Y, Cai X. Effect of CDKN2A/B rs4977756 polymorphism on glioma risk: a meta-analysis of 16 studies including 24077 participants. Mamm Genome 2015; 27:1-7. [PMID: 26577493 DOI: 10.1007/s00335-015-9612-9] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2015] [Accepted: 10/28/2015] [Indexed: 12/11/2022]
Abstract
So far, epidemiological studies have been performed to investigate the association of CDKN2A/B rs4977756 polymorphism and glioma risk. However, the results from different studies remain inconsistent. To clarify these conflicts and to quantitatively evaluate the effect of rs4977756 polymorphism on glioma risk, a meta-analysis was conducted using relevant published clinical studies about rs4977756 polymorphisms and glioma risk. Relevant studies concerning the association between rs4977756 polymorphism and risk of glioma were included in this meta-analysis. Odds ratio (OR) and 95 % confidence interval (CI) were calculated under fixed or random effects models when appropriate. Subgroup analyses were performed by race. This meta-analysis included 13 studies with a total of 8129 cases and 15,858 controls. The pooled results showed that there was an obvious association of CDKN2A/B rs4977756 polymorphism with risk of glioma in all four comparison models (dominant model/AG + GG vs. AA: OR = 1.36, 95 %CI = 1.20-1.54, p < 0.01; heterozygote comparison/AG vs. AA: OR = 1.31, 95 %CI = 1.12-1.53, p < 0.01; homozygote comparison/GG versus AA: OR = 1.49, 95 %CI = 1.36-1.64, p < 0.01; additive model/G vs. A: OR = 1.23, 95 %CI = 1.18-1.28, p < 0.01, respectively). For the subgroup analyses of ethnicities, similar results were observed in Caucasians. However, the association was not found between rs4977756 polymorphism and the risk of glioma in all models for the Asian studies. The CDKN2A/B rs4977756 polymorphism is obvious increase the risk of glioma in Caucasians. Future studies are needed to confirm the results in other ethnic populations.
Collapse
Affiliation(s)
- Xuchen Qi
- Department of Neurosurgery, Sir Run Run Shaw Hospital, College of Medical Sciences, Zhejiang University, Hangzhou, 310016, China
| | - Yingfeng Wan
- Department of Neurosurgery, Sir Run Run Shaw Hospital, College of Medical Sciences, Zhejiang University, Hangzhou, 310016, China
| | - Qitao Zhan
- Department of Reproductive Endocrinology, Women's Hospital, College of Medical Sciences, Zhejiang University, Hangzhou, 310006, China
| | - Shuxu Yang
- Department of Neurosurgery, Sir Run Run Shaw Hospital, College of Medical Sciences, Zhejiang University, Hangzhou, 310016, China
| | - Yirong Wang
- Department of Neurosurgery, Sir Run Run Shaw Hospital, College of Medical Sciences, Zhejiang University, Hangzhou, 310016, China
| | - Xiujun Cai
- Department of General Surgery, Sir Run Run Shaw Hospital, College of Medical Sciences, Zhejiang University, Hangzhou, 310016, China.
| |
Collapse
|
28
|
Claus EB, Walsh KM, Wiencke JK, Molinaro AM, Wiemels JL, Schildkraut JM, Bondy ML, Berger M, Jenkins R, Wrensch M. Survival and low-grade glioma: the emergence of genetic information. Neurosurg Focus 2015; 38:E6. [PMID: 25552286 DOI: 10.3171/2014.10.focus12367] [Citation(s) in RCA: 280] [Impact Index Per Article: 31.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Significant gaps exist in our understanding of the causes and clinical management of glioma. One of the biggest gaps is how best to manage low-grade (World Health Organization [WHO] Grade II) glioma. Low-grade glioma (LGG) is a uniformly fatal disease of young adults (mean age 41 years), with survival averaging approximately 7 years. Although LGG patients have better survival than patients with high-grade (WHO Grade III or IV) glioma, all LGGs eventually progress to high-grade glioma and death. Data from the Surveillance, Epidemiology and End Results (SEER) program of the National Cancer Institute suggest that for the majority of LGG patients, overall survival has not significantly improved over the past 3 decades, highlighting the need for intensified study of this tumor. Recently published research suggests that historically used clinical variables are not sufficient (and are likely inferior) prognostic and predictive indicators relative to information provided by recently discovered tumor markers (e.g., 1p/19q deletion and IDH1 or IDH2 mutation status), tumor expression profiles (e.g., the proneural profile) and/or constitutive genotype (e.g., rs55705857 on 8q24.21). Discovery of such tumor and constitutive variation may identify variables needed to improve randomization in clinical trials as well as identify patients more sensitive to current treatments and targets for improved treatment in the future. This article reports on survival trends for patients diagnosed with LGG within the United States from 1973 through 2011 and reviews the emerging role of tumor and constitutive genetics in refining risk stratification, defining targeted therapy, and improving survival for this group of relatively young patients.
Collapse
|
29
|
Rice T, Lachance DH, Molinaro AM, Eckel-Passow JE, Walsh KM, Barnholtz-Sloan J, Ostrom QT, Francis SS, Wiemels J, Jenkins RB, Wiencke JK, Wrensch MR. Understanding inherited genetic risk of adult glioma - a review. Neurooncol Pract 2015; 3:10-16. [PMID: 26941959 DOI: 10.1093/nop/npv026] [Citation(s) in RCA: 43] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2015] [Indexed: 01/10/2023] Open
Abstract
During the past six years, researchers have made major progress identifying common inherited genetic variation that increases risk for primary adult glioma. This paper summarizes knowledge about rare familial cancer syndromes that include adult glioma and reviews the available literature on the more recently discovered common inherited variation. Ten independent inherited variants in eight chromosomal regions have been convincingly associated with increased risk for adult glioma. Most of these variants increase relative risk of primary adult glioma by 20% to 40%, but the TP53 variant rs78378222 confers a two-fold relative risk (ie, 200%), and rs557505857 on chromosome 8 confers a six-fold relative risk of IDH-mutated astrocytomas and oligodendroglial tumors (ie, 600%). Even with a six-fold relative risk, the overall risk of developing adult glioma is too low for screening for the high-risk variant on chromosome 8. Future studies will help clarify which inherited adult glioma risk variants are associated with subtypes defined by histology and/or acquired tumor mutations. This review also provides an information sheet for primary adult glioma patients and their families.
Collapse
Affiliation(s)
- Terri Rice
- Division of Neuroepidemiology, Department of Neurological Surgery , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (T.R., A.M.M., K.M.W, S.S.F., J.W., J.K.W., M.R.W.); Department of Laboratory Medicine and Pathology , Mayo Clinic College of Medicine , 200 First Street SW, Rochester, MN 55905 (D.H.L., R.B.J.); Department of Neurology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905 (D.H.L.) ; Department of Epidemiology and Biostatistics , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (A.M.M., J.W.); Division of Biomedical Statistics and Informatics , Mayo Clinic College of Medicine , 200 First Street SW, Rochester, MN 55905 (J.E.E.-P.); Program in Cancer Genetics, Helen Diller Family Comprehensive Cancer Center , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (K.M.W., J.W., J.K.W., M.R.W.); Case Comprehensive Cancer Center , Case Western Reserve University School of Medicine , 11100 Euclid Avenue, Cleveland, OH 44106-5065 (J.B.-S., Q.T.O.); Central Brain Tumor Registry of the United States , 244 East Ogden Ave Suite 116, Hinsdale, IL 60521 (J.B.-S., Q.T.O.)
| | - Daniel H Lachance
- Division of Neuroepidemiology, Department of Neurological Surgery , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (T.R., A.M.M., K.M.W, S.S.F., J.W., J.K.W., M.R.W.); Department of Laboratory Medicine and Pathology , Mayo Clinic College of Medicine , 200 First Street SW, Rochester, MN 55905 (D.H.L., R.B.J.); Department of Neurology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905 (D.H.L.) ; Department of Epidemiology and Biostatistics , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (A.M.M., J.W.); Division of Biomedical Statistics and Informatics , Mayo Clinic College of Medicine , 200 First Street SW, Rochester, MN 55905 (J.E.E.-P.); Program in Cancer Genetics, Helen Diller Family Comprehensive Cancer Center , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (K.M.W., J.W., J.K.W., M.R.W.); Case Comprehensive Cancer Center , Case Western Reserve University School of Medicine , 11100 Euclid Avenue, Cleveland, OH 44106-5065 (J.B.-S., Q.T.O.); Central Brain Tumor Registry of the United States , 244 East Ogden Ave Suite 116, Hinsdale, IL 60521 (J.B.-S., Q.T.O.)
| | - Annette M Molinaro
- Division of Neuroepidemiology, Department of Neurological Surgery , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (T.R., A.M.M., K.M.W, S.S.F., J.W., J.K.W., M.R.W.); Department of Laboratory Medicine and Pathology , Mayo Clinic College of Medicine , 200 First Street SW, Rochester, MN 55905 (D.H.L., R.B.J.); Department of Neurology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905 (D.H.L.) ; Department of Epidemiology and Biostatistics , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (A.M.M., J.W.); Division of Biomedical Statistics and Informatics , Mayo Clinic College of Medicine , 200 First Street SW, Rochester, MN 55905 (J.E.E.-P.); Program in Cancer Genetics, Helen Diller Family Comprehensive Cancer Center , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (K.M.W., J.W., J.K.W., M.R.W.); Case Comprehensive Cancer Center , Case Western Reserve University School of Medicine , 11100 Euclid Avenue, Cleveland, OH 44106-5065 (J.B.-S., Q.T.O.); Central Brain Tumor Registry of the United States , 244 East Ogden Ave Suite 116, Hinsdale, IL 60521 (J.B.-S., Q.T.O.)
| | - Jeanette E Eckel-Passow
- Division of Neuroepidemiology, Department of Neurological Surgery , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (T.R., A.M.M., K.M.W, S.S.F., J.W., J.K.W., M.R.W.); Department of Laboratory Medicine and Pathology , Mayo Clinic College of Medicine , 200 First Street SW, Rochester, MN 55905 (D.H.L., R.B.J.); Department of Neurology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905 (D.H.L.) ; Department of Epidemiology and Biostatistics , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (A.M.M., J.W.); Division of Biomedical Statistics and Informatics , Mayo Clinic College of Medicine , 200 First Street SW, Rochester, MN 55905 (J.E.E.-P.); Program in Cancer Genetics, Helen Diller Family Comprehensive Cancer Center , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (K.M.W., J.W., J.K.W., M.R.W.); Case Comprehensive Cancer Center , Case Western Reserve University School of Medicine , 11100 Euclid Avenue, Cleveland, OH 44106-5065 (J.B.-S., Q.T.O.); Central Brain Tumor Registry of the United States , 244 East Ogden Ave Suite 116, Hinsdale, IL 60521 (J.B.-S., Q.T.O.)
| | - Kyle M Walsh
- Division of Neuroepidemiology, Department of Neurological Surgery , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (T.R., A.M.M., K.M.W, S.S.F., J.W., J.K.W., M.R.W.); Department of Laboratory Medicine and Pathology , Mayo Clinic College of Medicine , 200 First Street SW, Rochester, MN 55905 (D.H.L., R.B.J.); Department of Neurology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905 (D.H.L.) ; Department of Epidemiology and Biostatistics , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (A.M.M., J.W.); Division of Biomedical Statistics and Informatics , Mayo Clinic College of Medicine , 200 First Street SW, Rochester, MN 55905 (J.E.E.-P.); Program in Cancer Genetics, Helen Diller Family Comprehensive Cancer Center , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (K.M.W., J.W., J.K.W., M.R.W.); Case Comprehensive Cancer Center , Case Western Reserve University School of Medicine , 11100 Euclid Avenue, Cleveland, OH 44106-5065 (J.B.-S., Q.T.O.); Central Brain Tumor Registry of the United States , 244 East Ogden Ave Suite 116, Hinsdale, IL 60521 (J.B.-S., Q.T.O.)
| | - Jill Barnholtz-Sloan
- Division of Neuroepidemiology, Department of Neurological Surgery , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (T.R., A.M.M., K.M.W, S.S.F., J.W., J.K.W., M.R.W.); Department of Laboratory Medicine and Pathology , Mayo Clinic College of Medicine , 200 First Street SW, Rochester, MN 55905 (D.H.L., R.B.J.); Department of Neurology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905 (D.H.L.) ; Department of Epidemiology and Biostatistics , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (A.M.M., J.W.); Division of Biomedical Statistics and Informatics , Mayo Clinic College of Medicine , 200 First Street SW, Rochester, MN 55905 (J.E.E.-P.); Program in Cancer Genetics, Helen Diller Family Comprehensive Cancer Center , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (K.M.W., J.W., J.K.W., M.R.W.); Case Comprehensive Cancer Center , Case Western Reserve University School of Medicine , 11100 Euclid Avenue, Cleveland, OH 44106-5065 (J.B.-S., Q.T.O.); Central Brain Tumor Registry of the United States , 244 East Ogden Ave Suite 116, Hinsdale, IL 60521 (J.B.-S., Q.T.O.)
| | - Quinn T Ostrom
- Division of Neuroepidemiology, Department of Neurological Surgery , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (T.R., A.M.M., K.M.W, S.S.F., J.W., J.K.W., M.R.W.); Department of Laboratory Medicine and Pathology , Mayo Clinic College of Medicine , 200 First Street SW, Rochester, MN 55905 (D.H.L., R.B.J.); Department of Neurology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905 (D.H.L.) ; Department of Epidemiology and Biostatistics , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (A.M.M., J.W.); Division of Biomedical Statistics and Informatics , Mayo Clinic College of Medicine , 200 First Street SW, Rochester, MN 55905 (J.E.E.-P.); Program in Cancer Genetics, Helen Diller Family Comprehensive Cancer Center , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (K.M.W., J.W., J.K.W., M.R.W.); Case Comprehensive Cancer Center , Case Western Reserve University School of Medicine , 11100 Euclid Avenue, Cleveland, OH 44106-5065 (J.B.-S., Q.T.O.); Central Brain Tumor Registry of the United States , 244 East Ogden Ave Suite 116, Hinsdale, IL 60521 (J.B.-S., Q.T.O.)
| | - Stephen S Francis
- Division of Neuroepidemiology, Department of Neurological Surgery , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (T.R., A.M.M., K.M.W, S.S.F., J.W., J.K.W., M.R.W.); Department of Laboratory Medicine and Pathology , Mayo Clinic College of Medicine , 200 First Street SW, Rochester, MN 55905 (D.H.L., R.B.J.); Department of Neurology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905 (D.H.L.) ; Department of Epidemiology and Biostatistics , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (A.M.M., J.W.); Division of Biomedical Statistics and Informatics , Mayo Clinic College of Medicine , 200 First Street SW, Rochester, MN 55905 (J.E.E.-P.); Program in Cancer Genetics, Helen Diller Family Comprehensive Cancer Center , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (K.M.W., J.W., J.K.W., M.R.W.); Case Comprehensive Cancer Center , Case Western Reserve University School of Medicine , 11100 Euclid Avenue, Cleveland, OH 44106-5065 (J.B.-S., Q.T.O.); Central Brain Tumor Registry of the United States , 244 East Ogden Ave Suite 116, Hinsdale, IL 60521 (J.B.-S., Q.T.O.)
| | - Joseph Wiemels
- Division of Neuroepidemiology, Department of Neurological Surgery , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (T.R., A.M.M., K.M.W, S.S.F., J.W., J.K.W., M.R.W.); Department of Laboratory Medicine and Pathology , Mayo Clinic College of Medicine , 200 First Street SW, Rochester, MN 55905 (D.H.L., R.B.J.); Department of Neurology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905 (D.H.L.) ; Department of Epidemiology and Biostatistics , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (A.M.M., J.W.); Division of Biomedical Statistics and Informatics , Mayo Clinic College of Medicine , 200 First Street SW, Rochester, MN 55905 (J.E.E.-P.); Program in Cancer Genetics, Helen Diller Family Comprehensive Cancer Center , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (K.M.W., J.W., J.K.W., M.R.W.); Case Comprehensive Cancer Center , Case Western Reserve University School of Medicine , 11100 Euclid Avenue, Cleveland, OH 44106-5065 (J.B.-S., Q.T.O.); Central Brain Tumor Registry of the United States , 244 East Ogden Ave Suite 116, Hinsdale, IL 60521 (J.B.-S., Q.T.O.)
| | - Robert B Jenkins
- Division of Neuroepidemiology, Department of Neurological Surgery , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (T.R., A.M.M., K.M.W, S.S.F., J.W., J.K.W., M.R.W.); Department of Laboratory Medicine and Pathology , Mayo Clinic College of Medicine , 200 First Street SW, Rochester, MN 55905 (D.H.L., R.B.J.); Department of Neurology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905 (D.H.L.) ; Department of Epidemiology and Biostatistics , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (A.M.M., J.W.); Division of Biomedical Statistics and Informatics , Mayo Clinic College of Medicine , 200 First Street SW, Rochester, MN 55905 (J.E.E.-P.); Program in Cancer Genetics, Helen Diller Family Comprehensive Cancer Center , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (K.M.W., J.W., J.K.W., M.R.W.); Case Comprehensive Cancer Center , Case Western Reserve University School of Medicine , 11100 Euclid Avenue, Cleveland, OH 44106-5065 (J.B.-S., Q.T.O.); Central Brain Tumor Registry of the United States , 244 East Ogden Ave Suite 116, Hinsdale, IL 60521 (J.B.-S., Q.T.O.)
| | - John K Wiencke
- Division of Neuroepidemiology, Department of Neurological Surgery , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (T.R., A.M.M., K.M.W, S.S.F., J.W., J.K.W., M.R.W.); Department of Laboratory Medicine and Pathology , Mayo Clinic College of Medicine , 200 First Street SW, Rochester, MN 55905 (D.H.L., R.B.J.); Department of Neurology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905 (D.H.L.) ; Department of Epidemiology and Biostatistics , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (A.M.M., J.W.); Division of Biomedical Statistics and Informatics , Mayo Clinic College of Medicine , 200 First Street SW, Rochester, MN 55905 (J.E.E.-P.); Program in Cancer Genetics, Helen Diller Family Comprehensive Cancer Center , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (K.M.W., J.W., J.K.W., M.R.W.); Case Comprehensive Cancer Center , Case Western Reserve University School of Medicine , 11100 Euclid Avenue, Cleveland, OH 44106-5065 (J.B.-S., Q.T.O.); Central Brain Tumor Registry of the United States , 244 East Ogden Ave Suite 116, Hinsdale, IL 60521 (J.B.-S., Q.T.O.)
| | - Margaret R Wrensch
- Division of Neuroepidemiology, Department of Neurological Surgery , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (T.R., A.M.M., K.M.W, S.S.F., J.W., J.K.W., M.R.W.); Department of Laboratory Medicine and Pathology , Mayo Clinic College of Medicine , 200 First Street SW, Rochester, MN 55905 (D.H.L., R.B.J.); Department of Neurology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905 (D.H.L.) ; Department of Epidemiology and Biostatistics , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (A.M.M., J.W.); Division of Biomedical Statistics and Informatics , Mayo Clinic College of Medicine , 200 First Street SW, Rochester, MN 55905 (J.E.E.-P.); Program in Cancer Genetics, Helen Diller Family Comprehensive Cancer Center , University of California , San Francisco, 1450 3rd Street, San Francisco, CA 94158 (K.M.W., J.W., J.K.W., M.R.W.); Case Comprehensive Cancer Center , Case Western Reserve University School of Medicine , 11100 Euclid Avenue, Cleveland, OH 44106-5065 (J.B.-S., Q.T.O.); Central Brain Tumor Registry of the United States , 244 East Ogden Ave Suite 116, Hinsdale, IL 60521 (J.B.-S., Q.T.O.)
| |
Collapse
|
30
|
Wu Q, Peng Y, Zhao X. An Updated and Comprehensive Meta-Analysis of Association Between Seven Hot Loci Polymorphisms from Eight GWAS and Glioma Risk. Mol Neurobiol 2015; 53:4397-405. [DOI: 10.1007/s12035-015-9346-4] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2015] [Accepted: 07/07/2015] [Indexed: 12/12/2022]
|
31
|
Liu R, Li W, Wu C. A functional polymorphism in the pre‑miR‑146a gene influences the prognosis of glioblastoma multiforme by interfering with the balance between Notch1 and Notch2. Mol Med Rep 2015; 12:5475-81. [PMID: 26165719 DOI: 10.3892/mmr.2015.4067] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2014] [Accepted: 01/22/2015] [Indexed: 11/05/2022] Open
Abstract
The aim of the present study was to evaluate the association between a polymorphism (rs2910164) in the microRNA (miR)‑146a precursor and the prognosis of glioblastoma multiforme (GBM), as well as to examine the possible underlying mechanism in a Chinese population. A total of 380 patients with histologically confirmed GBM were recruited between 2008 and 2012, and were genotyped for the rs2910164 polymorphism using Sanger sequencing. The Kaplan‑Meier method was used to estimate overall survival (OS), and univariate and multivariate Cox proportional hazard regression analyses were used to evaluate the effect of miR‑146a polymorphisms on OS. It was identified that the rs2910164 CC genotype was significantly associated with a decreased OS among the patients with GBM (P=0.002). It was confirmed that Notch1 and Notch2 were targets of miR‑146a and it was demonstrated that the introduction of miR‑146a mimic suppressed the levels of Notch1 and Notch2 to different extents, resulting in a reduced Notch1/Notch2 ratio with an increase in miR‑146a mimic concentration in U251 cells. Additionally, resected tumor specimens were collected from 138 GBM patients and the expression levels of miR‑146a, Notch1 and Notch2 were examined using reverse transcription‑quantitative polymerase chain reaction and western blot analysis. Consistent with the in vitro study, lower levels of miR‑146a, higher levels of Notch1 and Notch2, and a higher Notch1/Notch2 ratio were identified in the CC genotype group compared with those of the GG/GC group. In the present study, the rs2910164 C allele was found to be associated with a reduced survival rate in patients with GBM, and the observed association between the CC genotype and poorer prognosis of GBM was at least partially mediated by the decreased expression of miR‑146a, which interfered with the balance of Notch1 and Notch2.
Collapse
Affiliation(s)
- Rongyao Liu
- Department of Neurosurgery, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116011, P.R. China
| | - Weihua Li
- Department of Neurosurgery, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116011, P.R. China
| | - Chunming Wu
- Department of Neurosurgery, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116011, P.R. China
| |
Collapse
|
32
|
Yang B, Heng L, Du S, Yang H, Jin T, Lang H, Li S. Association between RTEL1, PHLDB1, and TREH Polymorphisms and Glioblastoma Risk: A Case-Control Study. Med Sci Monit 2015; 21:1983-8. [PMID: 26156397 PMCID: PMC4507820 DOI: 10.12659/msm.893723] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
Abstract
Background Glioblastoma (GBM) is a highly invasive, aggressive, and incurable brain tumor. Genetic factors play important roles in GBM risk. The aim of this study was to elucidate the influence of gene polymorphism on GBM susceptibility. Material/Methods In this case-control study, we included 72 GBM patients and 320 healthy controls to analyze the association between 29 single-nucleotide polymorphisms and GBM cancer risk in the Chinese Han population. The single-nucleotide polymorphisms were determined by Sequenom MassARRAY RS1000 and statistical analysis was performed using SPSS software and SNPStats software. Results Using the χ2 test, we found that rs2297440 and rs6010620 in RTEL1 increased risk of GBM. In the recessive model, we also found that the genotypes “CC” of rs2297440 and “GG” of rs6010620 in RTEL1 significantly increased GBM risk. The variant TT genotype of TREH rs17748 and the variant TT genotype of PHLDB1 rs498872 decreased GBM risk in the recessive model. We also found that the TREH rs17748 variant C allele showed an increased risk in males in the dominant model. Conclusions Our results suggest a significant association between the RETL1, TREH, and PHLDB1 genes and GBM development in the Han Chinese population.
Collapse
Affiliation(s)
- Bo Yang
- Department of Outpatient, Tangdu Hospital, The Fourth Military Medical University, Xi'an, Shaanxi, China (mainland)
| | - Liang Heng
- Department of Medical, Tangdu Hospital, The Fourth Military Medical University, Xi'an, Shaanxi, China (mainland)
| | - Shuli Du
- School of Life Sciences, Northwest University, Xi'an, Shaanxi, China (mainland)
| | - Hua Yang
- School of Life Sciences, Northwest University, Xi'an, Shaanxi, China (mainland)
| | - Tianbo Jin
- School of Life Sciences, Northwest University, Xi'an, Shaanxi, China (mainland)
| | - Hongjun Lang
- Department of Nursing, Tangdu Hospital, The Fourth Military Medical University, Xi'an, Shaanxi, China (mainland)
| | - Shanqu Li
- Department of Outpatient, Tangdu Hospital, The Fourth Military Medical University, Xi'an, Shaanxi, China (mainland)
| |
Collapse
|
33
|
Abstract
Low-grade diffuse gliomas are a heterogeneous group of primary glial brain tumors with highly variable survival. Currently, patients with low-grade diffuse gliomas are stratified into risk subgroups by subjective histopathologic criteria with significant interobserver variability. Several key molecular signatures have emerged as diagnostic, prognostic, and predictor biomarkers for tumor classification and patient risk stratification. In this review, we discuss the effect of the most critical molecular alterations described in diffuse (IDH1/2, 1p/19q codeletion, ATRX, TERT, CIC, and FUBP1) and circumscribed (BRAF-KIAA1549, BRAF(V600E), and C11orf95-RELA fusion) gliomas. These molecular features reflect tumor heterogeneity and have specific associations with patient outcome that determine appropriate patient management. This has led to an important, fundamental shift toward developing a molecular classification of World Health Organization grade II-III diffuse glioma.
Collapse
Affiliation(s)
- Adriana Olar
- Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - Erik P Sulman
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
| |
Collapse
|
34
|
Cao JL, Yuan P, Abuduwufuer A, Lv W, Yang YH, Hu J. Association between the TERT Genetic Polymorphism rs2853676 and Cancer Risk: Meta-Analysis of 76,108 Cases and 134,215 Controls. PLoS One 2015; 10:e0128829. [PMID: 26042809 PMCID: PMC4456375 DOI: 10.1371/journal.pone.0128829] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2015] [Accepted: 04/30/2015] [Indexed: 12/14/2022] Open
Abstract
Background Several recent studies have identified that the TERT genetic polymorphism rs2853676 is associated with cancer risk, but presented inconsistent results. We investigated these inconclusive results by performing a meta-analysis to systematically evaluate the association. Methods We conducted a search in PubMed, Google Scholar and ISI Web of Science to select studies on the association between TERT rs2853676 and cancer risk. We conducted a stratified analysis using cancer type, ethnicity and source of controls. We calculated the odds ratios (OR) and 95% confidence intervals (CI). Article quality, heterogeneity, sensitivity, publication bias and statistical power were also assessed. Results 26 articles covering 76 108 cases and 134 215 controls met our inclusion criteria. A significant association between TERT rs2853676 allele A and cancer susceptibility was demonstrated under a per-allele risk analysis (OR = 1.08, 95% CI = 1.04-1.13). Stratification analysis revealed an increased cancer risk in subgroups of glioma, lung cancer and ovarian cancer. No significant increase was found in melanoma, breast cancer, pancreatic cancer and colorectal cancer. In a subgroup analysis of lung cancer, a statistically significant increase was only observed in adenocarcinoma. Moreover, a stratified analysis performed for ethnic groups revealed that the significant increase was only observed in Caucasians, whereas a non-significant increase was found in Asians. Conclusions This meta-analysis suggests that the TERT genetic polymorphism rs2853676 is associated with increased risk of glioma, lung adenocarcinoma and ovarian cancer among Caucasians. Further functional studies are warranted to validate this association and investigate further.
Collapse
Affiliation(s)
- Jin-Lin Cao
- Department of Thoracic Surgery, The first Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
| | - Ping Yuan
- Department of Thoracic Surgery, The first Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
| | - Abudumailamu Abuduwufuer
- Department of Thoracic Surgery, The first Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
| | - Wang Lv
- Department of Thoracic Surgery, The first Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
| | - Yun-Hai Yang
- Department of Thoracic Surgery, The first Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
| | - Jian Hu
- Department of Thoracic Surgery, The first Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
- * E-mail:
| |
Collapse
|
35
|
Rapkins RW, Wang F, Nguyen HN, Cloughesy TF, Lai A, Ha W, Nowak AK, Hitchins MP, McDonald KL. The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide. Neuro Oncol 2015; 17:1589-98. [PMID: 25910840 DOI: 10.1093/neuonc/nov064] [Citation(s) in RCA: 47] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2014] [Accepted: 03/20/2015] [Indexed: 12/20/2022] Open
Abstract
BACKGROUND Promoter methylation of O(6)-methylguanine-DNA methyltransferase (MGMT) is an important predictive biomarker in glioblastoma. The T variant of the MGMT promoter-enhancer single nucleotide polymorphism (SNP; rs16906252) has been associated with the presence of MGMT promoter methylation in other cancers. We examined the association of the T allele of rs16906252 with glioblastoma development, tumor MGMT methylation, MGMT protein expression, and survival outcomes. METHODS Two independent temozolomide-treated glioblastoma cohorts-one Australian (Australian Genomics and Clinical Outcomes of Glioma, n = 163) and the other American (University of California Los Angeles/Kaiser Permanente Los Angeles, n = 159)-were studied. Allelic bisulphite sequencing was used to determine if methylation was specific to the T allele. Additionally, we compared the incidence of the T allele between glioblastoma cases and matched controls to assess whether it was a risk factor for developing MGMT methylated glioblastoma. RESULTS Carriage of the T allele of the rs16906252 SNP was associated with both MGMT methylation and low MGMT protein expression and predicted significantly longer survival in temozolomide-treated patients with both MGMT methylated and nonmethylated glioblastoma. Methylation was linked to the T allele, inferring that the T variant plays a key role in the acquisition of MGMT methylation. Carriage of the T allele was associated with a significantly elevated risk of developing glioblastoma (adjusted odds ratio, 1.96; P = .013), increasing further when glioblastoma was classified by the presence of MGMT methylation (adjusted odds ratio, 2.86; P = .001). CONCLUSIONS The T allele of the rs16906252 SNP is a key determinant in the acquisition of MGMT methylation in glioblastoma. Temozolomide-treated patients with the rs16906252 T genotype have better survival, irrespective of tumor methylation status.
Collapse
Affiliation(s)
- Robert W Rapkins
- Cure Brain Cancer Neuro-oncology Laboratory, Prince of Wales Clinical School, Lowy Cancer Research Centre, University of New South Wales, Sydney, Australia (R.W.R., W.H., K.L.M.); Department of Medicine (Oncology), Stanford Cancer Institute, Stanford University, Stanford, California (F.W., M.P.H.); School of Public Health, Harbin Medical University, Harbin, People's Republic of China (F.W.); Department of Neurology, David Geffen School of Medicine at UCLA, University of California at Los Angeles, Los Angeles, California (H.N.N., T.F.C., A.L.); School of Medicine and Pharmacology, University of Western Australia, Perth, Australia (A.N.)
| | - Fan Wang
- Cure Brain Cancer Neuro-oncology Laboratory, Prince of Wales Clinical School, Lowy Cancer Research Centre, University of New South Wales, Sydney, Australia (R.W.R., W.H., K.L.M.); Department of Medicine (Oncology), Stanford Cancer Institute, Stanford University, Stanford, California (F.W., M.P.H.); School of Public Health, Harbin Medical University, Harbin, People's Republic of China (F.W.); Department of Neurology, David Geffen School of Medicine at UCLA, University of California at Los Angeles, Los Angeles, California (H.N.N., T.F.C., A.L.); School of Medicine and Pharmacology, University of Western Australia, Perth, Australia (A.N.)
| | - HuyTram N Nguyen
- Cure Brain Cancer Neuro-oncology Laboratory, Prince of Wales Clinical School, Lowy Cancer Research Centre, University of New South Wales, Sydney, Australia (R.W.R., W.H., K.L.M.); Department of Medicine (Oncology), Stanford Cancer Institute, Stanford University, Stanford, California (F.W., M.P.H.); School of Public Health, Harbin Medical University, Harbin, People's Republic of China (F.W.); Department of Neurology, David Geffen School of Medicine at UCLA, University of California at Los Angeles, Los Angeles, California (H.N.N., T.F.C., A.L.); School of Medicine and Pharmacology, University of Western Australia, Perth, Australia (A.N.)
| | - Timothy F Cloughesy
- Cure Brain Cancer Neuro-oncology Laboratory, Prince of Wales Clinical School, Lowy Cancer Research Centre, University of New South Wales, Sydney, Australia (R.W.R., W.H., K.L.M.); Department of Medicine (Oncology), Stanford Cancer Institute, Stanford University, Stanford, California (F.W., M.P.H.); School of Public Health, Harbin Medical University, Harbin, People's Republic of China (F.W.); Department of Neurology, David Geffen School of Medicine at UCLA, University of California at Los Angeles, Los Angeles, California (H.N.N., T.F.C., A.L.); School of Medicine and Pharmacology, University of Western Australia, Perth, Australia (A.N.)
| | - Albert Lai
- Cure Brain Cancer Neuro-oncology Laboratory, Prince of Wales Clinical School, Lowy Cancer Research Centre, University of New South Wales, Sydney, Australia (R.W.R., W.H., K.L.M.); Department of Medicine (Oncology), Stanford Cancer Institute, Stanford University, Stanford, California (F.W., M.P.H.); School of Public Health, Harbin Medical University, Harbin, People's Republic of China (F.W.); Department of Neurology, David Geffen School of Medicine at UCLA, University of California at Los Angeles, Los Angeles, California (H.N.N., T.F.C., A.L.); School of Medicine and Pharmacology, University of Western Australia, Perth, Australia (A.N.)
| | - Wendy Ha
- Cure Brain Cancer Neuro-oncology Laboratory, Prince of Wales Clinical School, Lowy Cancer Research Centre, University of New South Wales, Sydney, Australia (R.W.R., W.H., K.L.M.); Department of Medicine (Oncology), Stanford Cancer Institute, Stanford University, Stanford, California (F.W., M.P.H.); School of Public Health, Harbin Medical University, Harbin, People's Republic of China (F.W.); Department of Neurology, David Geffen School of Medicine at UCLA, University of California at Los Angeles, Los Angeles, California (H.N.N., T.F.C., A.L.); School of Medicine and Pharmacology, University of Western Australia, Perth, Australia (A.N.)
| | - Anna K Nowak
- Cure Brain Cancer Neuro-oncology Laboratory, Prince of Wales Clinical School, Lowy Cancer Research Centre, University of New South Wales, Sydney, Australia (R.W.R., W.H., K.L.M.); Department of Medicine (Oncology), Stanford Cancer Institute, Stanford University, Stanford, California (F.W., M.P.H.); School of Public Health, Harbin Medical University, Harbin, People's Republic of China (F.W.); Department of Neurology, David Geffen School of Medicine at UCLA, University of California at Los Angeles, Los Angeles, California (H.N.N., T.F.C., A.L.); School of Medicine and Pharmacology, University of Western Australia, Perth, Australia (A.N.)
| | - Megan P Hitchins
- Cure Brain Cancer Neuro-oncology Laboratory, Prince of Wales Clinical School, Lowy Cancer Research Centre, University of New South Wales, Sydney, Australia (R.W.R., W.H., K.L.M.); Department of Medicine (Oncology), Stanford Cancer Institute, Stanford University, Stanford, California (F.W., M.P.H.); School of Public Health, Harbin Medical University, Harbin, People's Republic of China (F.W.); Department of Neurology, David Geffen School of Medicine at UCLA, University of California at Los Angeles, Los Angeles, California (H.N.N., T.F.C., A.L.); School of Medicine and Pharmacology, University of Western Australia, Perth, Australia (A.N.)
| | - Kerrie L McDonald
- Cure Brain Cancer Neuro-oncology Laboratory, Prince of Wales Clinical School, Lowy Cancer Research Centre, University of New South Wales, Sydney, Australia (R.W.R., W.H., K.L.M.); Department of Medicine (Oncology), Stanford Cancer Institute, Stanford University, Stanford, California (F.W., M.P.H.); School of Public Health, Harbin Medical University, Harbin, People's Republic of China (F.W.); Department of Neurology, David Geffen School of Medicine at UCLA, University of California at Los Angeles, Los Angeles, California (H.N.N., T.F.C., A.L.); School of Medicine and Pharmacology, University of Western Australia, Perth, Australia (A.N.)
| |
Collapse
|
36
|
Cui T. CCDC26 rs4295627 polymorphism and glioma risk: a meta-analysis. Int J Clin Exp Med 2015; 8:3862-3868. [PMID: 26064285 PMCID: PMC4443119] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2014] [Accepted: 02/06/2015] [Indexed: 06/04/2023]
Abstract
Several studies have examined the association of CCDC26 rs4295627 polymorphism and glioma risk. However, the results were conflicting. Thus, a meta-analysis was conducted. We searched for relevant studies up to Dec 2014 in both English and Chinese through the PubMed/MEDLINE, EMBASE, the China National Knowledge Infrastructure (CNKI) platforms, WanFang and VIP database. Overall, 14 studies with 17419 cases and 28465 controls were selected for final meta-analysis. CCDC26 rs4295627 polymorphism was significantly associated with an increased risk of glioma (OR = 1.25, 95% CI 1.15-1.36, P < 0.00001). Interestingly, CCDC26 rs4295627 polymorphism might decrease the risk of glioma in Asians (OR = 0.92, 95% CI 0.82-1.03, P = 0.15). However, Caucasians with CCDC26 rs4295627 polymorphism showed an increased risk of glioma (OR = 1.33, 95% CI 1.25-1.46, P < 0.00001). Subgroup analysis was performed by histology. Significant associations were observed among astrocytoma patients (OR = 1.31, 95% CI 1.17-1.47, P < 0.00001) and oligodendroglioma patients (OR = 1.79, 95% CI 1.47-2.17, P < 0.00001). No significant association was found between this polymorphism and glioblastoma risk (OR = 0.11, 95% CI 0.92-1.33, P = 0.28). This meta-analysis suggested that CCDC26 rs4295627 polymorphism was a risk factor for glioma.
Collapse
Affiliation(s)
- Tao Cui
- Department of Neurosurgery, The Firet Affiliated Hospital of Henan University of Science and Technology Luoyang 471003, Henan, China
| |
Collapse
|
37
|
Jung Y, Huang JZ, Hu J. Biomarker Detection in Association Studies: Modeling SNPs Simultaneously via Logistic ANOVA. J Am Stat Assoc 2014; 109:1355-1367. [PMID: 25642005 DOI: 10.1080/01621459.2014.928217] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Abstract
In genome-wide association studies, the primary task is to detect biomarkers in the form of Single Nucleotide Polymorphisms (SNPs) that have nontrivial associations with a disease phenotype and some other important clinical/environmental factors. However, the extremely large number of SNPs comparing to the sample size inhibits application of classical methods such as the multiple logistic regression. Currently the most commonly used approach is still to analyze one SNP at a time. In this paper, we propose to consider the genotypes of the SNPs simultaneously via a logistic analysis of variance (ANOVA) model, which expresses the logit transformed mean of SNP genotypes as the summation of the SNP effects, effects of the disease phenotype and/or other clinical variables, and the interaction effects. We use a reduced-rank representation of the interaction-effect matrix for dimensionality reduction, and employ the L1-penalty in a penalized likelihood framework to filter out the SNPs that have no associations. We develop a Majorization-Minimization algorithm for computational implementation. In addition, we propose a modified BIC criterion to select the penalty parameters and determine the rank number. The proposed method is applied to a Multiple Sclerosis data set and simulated data sets and shows promise in biomarker detection.
Collapse
Affiliation(s)
- Yoonsuh Jung
- Department of Statistics, Univerisity of Waikato, Private Bag 3105, Hamilton 3240, New Zealand
| | - Jianhua Z Huang
- Department of Statistics, Texas A&M University, College Station, TX, USA, and Special Term Professor at ISEM, Captial University of Economics and Business, Beijing, China
| | - Jianhua Hu
- Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| |
Collapse
|
38
|
Assessment of glioma risk associated with an inherited variant at chromosome 11q23. Cell Biochem Biophys 2014; 71:69-75. [PMID: 25182002 DOI: 10.1007/s12013-014-0164-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
It is still unclear whether or not rs498872 at 11q23.3 increases the risk of developing glioma, because the previous literature has reported mixed findings. We carried out a meta-analysis with an aim to test the hypothesis that rs498872 contributes to the development of glioma. Eligible studies were identified through databases including the Chinese biomedical literature database, China national knowledge infrastructure, Science Direct, Embase and PubMed. The risk of glioma (OR and 95% CI) was evaluated with the fixed-effects model or the random-effects model. Sensitivity analysis and publication bias tests were performed to check the reliability of our findings. Ten independent populations representing three ethnicities were analyzed in this study. We found 1.17-1.34-fold increased risk of glioma associated with rs498872 genotypes (OR 1.34, 95% CI 1.22-1.46; OR 1.24, 95% CI 1.14-1.35; OR 1.20, 95% CI 1.10-1.31; OR 1.17, 95% CI 1.08-1.27). In the stratified analysis by ethnicity, we also observed a significant increase in the risk of glioma in both Americans and Europeans. The results of our study support that the rs498872 polymorphism at 11q23.3 locus may be an important risk factor for glioma risk.
Collapse
|
39
|
Gabriel A, Batey J, Capogreco J, Kimball D, Walters A, Tubbs RS, Loukas M. Adult brain cancer in the U.S. black population: a Surveillance, Epidemiology, and End Results (SEER) analysis of incidence, survival, and trends. Med Sci Monit 2014; 20:1510-7. [PMID: 25151984 PMCID: PMC4156338 DOI: 10.12659/msm.890762] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
Background Despite much epidemiological research on brain cancer in the United States, the etiology for the various subtypes remains elusive. The black population in the United States currently experiences lower incidence but higher survival rates when compared to other races. Thus, the aim of this study is to analyze the trends in incidence and survival for the 6 most common primary brain tumors in the black population of the United States. Material/Methods The Surveillance, Epidemiology, and End Results (SEER) database was utilized in this study to analyze the incidence and survival rates for the 6 most common brain tumor subtypes. Joinpoint 3.5.2 software was used to analyze trends in the incidence of diagnosis from 1973 to 2008. A Kaplan-Meier curve was generated to analyze mean time to death and survival at 60 months. Results Joinpoint analysis revealed that per year the incidence of brain cancer in the U.S. black population increased by 0.11 between 1973 and 1989. After this period, a moderate decrease by 0.06 per annum was observed from 1989 to 2008. Lymphoma was the most common primary tumor subtype for black individuals ages 20–34, and glioblastoma was identified as the most common tumor subtype for black individuals in the age groups of 35–49, 50–64, 65–79, and 80+. Conclusions This population-based retrospective study of brain cancer in black adults in the United States revealed significant sex and age differences in the incidence of the 6 most common brain tumor subtypes from 1973 to 2008.
Collapse
Affiliation(s)
- Abigail Gabriel
- School of Medicine, St. George's University, St. George, Grenada
| | - Jason Batey
- School of Medicine, St. George's University, St. George, Grenada
| | - Joseph Capogreco
- School of Medicine, St. George's University, St. George, Grenada
| | - David Kimball
- School of Medicine, St. George's University, St. George, Grenada
| | - Andy Walters
- School of Medicine, St. George's University, St. George, Grenada
| | - R Shane Tubbs
- Department of Pediatric Neurosurgery, Childrens Hospital, Birmingham , USA
| | - Marios Loukas
- School of Medicine, St. George's University, St. George, Grenada
| |
Collapse
|
40
|
Vannier JB, Sarek G, Boulton SJ. RTEL1: functions of a disease-associated helicase. Trends Cell Biol 2014; 24:416-25. [PMID: 24582487 DOI: 10.1016/j.tcb.2014.01.004] [Citation(s) in RCA: 85] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2013] [Revised: 01/25/2014] [Accepted: 01/27/2014] [Indexed: 11/29/2022]
Abstract
DNA secondary structures that arise during DNA replication, repair, and recombination (3R) must be processed correctly to prevent genetic instability. Regulator of telomere length 1 (RTEL1) is an essential DNA helicase that disassembles a variety of DNA secondary structures to facilitate 3R processes and to maintain telomere integrity. The past few years have witnessed the emergence of RTEL1 variants that confer increased susceptibility to high-grade glioma, astrocytomas, and glioblastomas. Mutations in RTEL1 have also been implicated in Hoyeraal-Hreidarsson syndrome, a severe form of the bone-marrow failure and cancer predisposition disorder, dyskeratosis congenita. We review these recent findings and highlight its crucial link between DNA secondary-structure metabolism and human disease.
Collapse
Affiliation(s)
- Jean-Baptiste Vannier
- DNA Damage Response Laboratory, London Research Institute, Cancer Research UK, Clare Hall, South Mimms, EN6 3LD, UK
| | - Grzegorz Sarek
- DNA Damage Response Laboratory, London Research Institute, Cancer Research UK, Clare Hall, South Mimms, EN6 3LD, UK
| | - Simon J Boulton
- DNA Damage Response Laboratory, London Research Institute, Cancer Research UK, Clare Hall, South Mimms, EN6 3LD, UK.
| |
Collapse
|
41
|
Bharti SK, Khan I, Banerjee T, Sommers JA, Wu Y, Brosh RM. Molecular functions and cellular roles of the ChlR1 (DDX11) helicase defective in the rare cohesinopathy Warsaw breakage syndrome. Cell Mol Life Sci 2014; 71:2625-39. [PMID: 24487782 PMCID: PMC4537069 DOI: 10.1007/s00018-014-1569-4] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2013] [Revised: 01/07/2014] [Accepted: 01/16/2014] [Indexed: 02/08/2023]
Abstract
In 2010, a new recessive cohesinopathy disorder, designated Warsaw breakage syndrome (WABS), was described. The individual with WABS displayed microcephaly, pre- and postnatal growth retardation, and abnormal skin pigmentation. Cytogenetic analysis revealed mitomycin C (MMC)-induced chromosomal breakage; however, an additional sister chromatid cohesion defect was also observed. WABS is genetically linked to bi-allelic mutations in the ChlR1/DDX11 gene which encodes a protein of the conserved family of Iron-Sulfur (Fe-S) cluster DNA helicases. Mutations in the budding yeast ortholog of ChlR1, known as Chl1, were known to cause sister chromatid cohesion defects, indicating a conserved function of the gene. In 2012, three affected siblings were identified with similar symptoms to the original WABS case, and found to have a homozygous mutation in the conserved Fe-S domain of ChlR1, confirming the genetic linkage. Significantly, the clinically relevant mutations perturbed ChlR1 DNA unwinding activity. In addition to its genetic importance in human disease, ChlR1 is implicated in papillomavirus genome maintenance and cancer. Although its precise functions in genome homeostasis are still not well understood, ongoing molecular studies of ChlR1 suggest the helicase plays a critically important role in cellular replication and/or DNA repair.
Collapse
Affiliation(s)
- Sanjay Kumar Bharti
- Laboratory of Molecular Gerontology, National Institute on Aging, National Institutes of Health, NIH Biomedical Research Center, Baltimore, MD 21224 USA
| | - Irfan Khan
- Laboratory of Molecular Gerontology, National Institute on Aging, National Institutes of Health, NIH Biomedical Research Center, Baltimore, MD 21224 USA
| | - Taraswi Banerjee
- Laboratory of Molecular Gerontology, National Institute on Aging, National Institutes of Health, NIH Biomedical Research Center, Baltimore, MD 21224 USA
| | - Joshua A. Sommers
- Laboratory of Molecular Gerontology, National Institute on Aging, National Institutes of Health, NIH Biomedical Research Center, Baltimore, MD 21224 USA
| | - Yuliang Wu
- Department of Biochemistry, University of Saskatchewan, Saskatoon, SK S7N 5E5 Canada
| | - Robert M. Brosh
- Laboratory of Molecular Gerontology, National Institute on Aging, National Institutes of Health, NIH Biomedical Research Center, Baltimore, MD 21224 USA
| |
Collapse
|
42
|
Gao X, Mi Y, Yan A, Sha B, Guo N, Hu Z, Zhang N, Jiang F, Gou X. The PHLDB1 rs498872 (11q23.3) polymorphism and glioma risk: A meta-analysis. Asia Pac J Clin Oncol 2014; 11:e13-21. [PMID: 24935770 DOI: 10.1111/ajco.12211] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/04/2014] [Indexed: 01/04/2023]
Abstract
The association between the rs498872 single nucleotide polymorphism (SNP) and glioma risk has been studied, but these studies have yielded conflicting results. In order to explore this association, we performed a meta-analysis. A comprehensive literature search was performed using PubMed and EMBASE database, with the last search up to August 23, 2013. Six articles including 10 case-control studies in English with 18 002 controls and 8434 cases were eligible for the meta-analysis. Subgroup analyses were conducted by source of controls and ethnicity. The combined results showed that rs498872 polymorphism was significantly associated with glioma risks (TT vs CC: OR = 1.337, 95% CI = 1.222-1.462; TC vs CC: OR = 1.173, 95% CI = 1.081-1.272; dominant model: OR = 1.199, 95% CI = 1.101-1.306; recessive model: OR = 1.237, 95% CI = 1.135-1.347; additive model: OR = 1.156, 95% CI = 1.085-1.232). Moreover, there was increased cancer risk in all genetic models after stratification of the SNP data by the source of controls and ethnicity, and no evidence of publication bias was produced. Our meta-analysis suggested that rs498872 polymorphism was associated with increased risk of glioma. However, additional studies exploring the combined effects of rs498872 polymorphisms in Asian population should be investigated.
Collapse
Affiliation(s)
- Xingchun Gao
- Institute of Basic Medical Science, Xi'an Medical University, Xi'an, China
| | - Yajing Mi
- Institute of Basic Medical Science, Xi'an Medical University, Xi'an, China
| | - Aili Yan
- Institute of Basic Medical Science, Xi'an Medical University, Xi'an, China
| | - Baoyong Sha
- Institute of Basic Medical Science, Xi'an Medical University, Xi'an, China
| | - Na Guo
- Institute of Basic Medical Science, Xi'an Medical University, Xi'an, China
| | - Zhifang Hu
- Institute of Basic Medical Science, Xi'an Medical University, Xi'an, China
| | - Ni Zhang
- Institute of Basic Medical Science, Xi'an Medical University, Xi'an, China
| | - Fengliang Jiang
- Institute of Basic Medical Science, Xi'an Medical University, Xi'an, China
| | - Xingchun Gou
- Institute of Basic Medical Science, Xi'an Medical University, Xi'an, China
| |
Collapse
|
43
|
Egan KM, Baskin R, Nabors LB, Thompson RC, Olson JJ, Browning JE, Madden MH, Monteiro AN. Brain tumor risk according to germ-line variation in the MLLT10 locus. Eur J Hum Genet 2014; 23:132-4. [PMID: 24755950 DOI: 10.1038/ejhg.2014.70] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2013] [Revised: 01/17/2014] [Accepted: 03/18/2014] [Indexed: 01/04/2023] Open
Abstract
Genome-wide association studies have recently identified a cancer susceptibility locus at 10p12 mapping to MLLT10 associated with the onset of diverse tumors. We genotyped two tightly linked single-nucleotide polymorphisms (SNPs) at MLLT10 associated with meningioma (rs12770228) or ovarian cancer (rs1243180), and tested for associations among 295 meningioma cases, 606 glioma cases and 646 noncancer controls, all of European descent. The variant 'A' allele in MLLT10 rs12770228 was associated with an increased risk of meningioma (per allele odds ratio: 1.25; 95% confidence interval: 1.02, 1.53; P=0.031). Similar associations were observed for rs1243180. MLLT10 variants were unrelated to glioma. Functional investigation identified 22 candidate functional SNPs mapping to this region. The present study further validates 10p12 as a meningioma risk locus.
Collapse
Affiliation(s)
- Kathleen M Egan
- Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
| | - Rebekah Baskin
- Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
| | - L Burton Nabors
- Neuro-oncology Program, University of Alabama at Birmingham, Birmingham, AL, USA
| | - Reid C Thompson
- Department of Neurosurgery, Emory School of Medicine, Atlanta, GA, USA
| | - Jeffrey J Olson
- Department of Neurological Surgery, Vanderbilt University Medical Center, Nashville, TN, USA
| | - James E Browning
- Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
| | - Melissa H Madden
- Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
| | - Alvaro N Monteiro
- Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
| |
Collapse
|
44
|
Zhou P, Wei L, Xia X, Shao N, Qian X, Yang Y. Association between telomerase reverse transcriptase rs2736100 polymorphism and risk of glioma. J Surg Res 2014; 191:156-60. [PMID: 24888789 DOI: 10.1016/j.jss.2014.03.043] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2014] [Revised: 02/22/2014] [Accepted: 03/14/2014] [Indexed: 12/12/2022]
Abstract
BACKGROUND Epidemiological studies have been conducted to investigate the association of telomerase reverse transcriptase (TERT) rs2736100 polymorphism with glioma risk. The aim of the present study was to evaluate the association of TERT rs2736100 polymorphism with glioma risk using a meta-analysis approach. MATERIALS AND METHODS All eligible studies were identified through a search of PubMed, EMBASE, China National Knowledge Infrastructure, Database of Chinese Scientific and Technical Periodicals, and China Biology Medical literature database before January 2014. The association between the TERT rs2736100 polymorphism and glioma risk was estimated by odds ratio (OR) and 95% confidence interval (CI). RESULTS A total of nine case-control studies including 9411 cases and 13,708 controls were eventually collected. Overall, we found that TERT rs2736100 polymorphism was significantly associated with the risk of glioma (OR = 1.29, 95% CI 1.24-1.34, P < 0.001). In the subgroup analysis based on ethnicity, the significant association was found in Caucasians (OR = 1.29, 95% CI 1.24-1.34, P < 0.001). In subgroup analyses by histology, the associations were significant in glioblastoma (OR = 1.45, 95% CI 1.32-1.60, P < 0.001), astrocytoma (OR = 1.41, 95% CI 1.26-1.58, P < 0.001), and oligodendroglioma (OR = 1.20, 95% CI 1.05-1.37, P = 0.008). CONCLUSIONS Taken together, these data suggested that TERT rs2736100 polymorphism may contribute to glioma susceptibility.
Collapse
Affiliation(s)
- Peng Zhou
- Department of Neurosurgery, The First People's Hospital of Changzhou, Changzhou, Jiangsu Province, China
| | - Li Wei
- Department of Transfusion, The First People's Hospital of Changzhou, Changzhou, Jiangsu Province, China
| | - Xiwei Xia
- Department of Neurosurgery, The First People's Hospital of Changzhou, Changzhou, Jiangsu Province, China
| | - Naiyuan Shao
- Department of Neurosurgery, The First People's Hospital of Changzhou, Changzhou, Jiangsu Province, China
| | - Xinyu Qian
- Department of Transfusion, The First People's Hospital of Changzhou, Changzhou, Jiangsu Province, China
| | - Yilin Yang
- Department of Neurosurgery, The First People's Hospital of Changzhou, Changzhou, Jiangsu Province, China.
| |
Collapse
|
45
|
Madden MH, Anic GM, Thompson RC, Nabors LB, Olson JJ, Browning JE, Monteiro AN, Egan KM. Circadian pathway genes in relation to glioma risk and outcome. Cancer Causes Control 2014; 25:25-32. [PMID: 24135790 PMCID: PMC3947318 DOI: 10.1007/s10552-013-0305-y] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2013] [Accepted: 10/08/2013] [Indexed: 12/11/2022]
Abstract
PURPOSE There is growing evidence that circadian disruption may alter risk and aggressiveness of cancer. We evaluated common genetic variants in the circadian gene pathway for associations with glioma risk and patient outcome in a US clinic-based case-control study. METHODS Subjects were genotyped for 17 candidate single nucleotide polymorphisms in ARNTL, CRY1, CRY2, CSNK1E, KLHL30, NPAS2, PER1, PER3, CLOCK, and MYRIP. Unconditional logistic regression was used to estimate age and gender-adjusted odds ratios (OR) and 95 % confidence intervals (CI) for glioma risk under three inheritance models (additive, dominant, and recessive). Proportional hazards regression was used to estimate hazard ratios for glioma-related death among 441 patients with high-grade tumors. Survival associations were validated using The Cancer Genome Atlas (TCGA) dataset. RESULTS A variant in PER1 (rs2289591) was significantly associated with overall glioma risk (per variant allele OR 0.80; 95 % CI 0.66-0.97; p trend = 0.027). The variant allele for CLOCK rs11133391 under a recessive model increased risk of oligodendroglioma (OR 2.41; 95 % CI 1.31-4.42; p = 0.005), though not other glioma subtypes (p for heterogeneity = 0.0033). The association remained significant after false discovery rate adjustment (p = 0.008). Differential associations by gender were observed for MYRIP rs6599077 and CSNK1E rs1534891 though differences were not significant after adjustment for multiple testing. No consistent mortality associations were identified. Several of the examined genes exhibited differential expression in glioblastoma multiforme versus normal brain in TCGA data (MYRIP, ARNTL, CRY1, KLHL30, PER1, CLOCK, and PER3), and expression of NPAS2 was significantly associated with a poor patient outcome in TCGA patients. CONCLUSION This exploratory analysis provides some evidence supporting a role for circadian genes in the onset of glioma and possibly the outcome of glioma.
Collapse
Affiliation(s)
- Melissa H. Madden
- Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center & Research Institute, Tampa FL 33612, USA
| | - Gabriella M. Anic
- Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center & Research Institute, Tampa FL 33612, USA
| | - Reid C. Thompson
- Department of Neurological Surgery, Vanderbilt University Medical Center, Nashville, TN 37232, USA
| | - L. Burton Nabors
- Neuro-oncology Program, University of Alabama at Birmingham, Birmingham, AL 35294, USA
| | - Jeffrey J. Olson
- Department of Neurosurgery, Emory School of Medicine, Atlanta, GA 30322, USA
| | - James E. Browning
- Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center & Research Institute, Tampa FL 33612, USA
| | - Alvaro N. Monteiro
- Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center & Research Institute, Tampa FL 33612, USA
| | - Kathleen M. Egan
- Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center & Research Institute, Tampa FL 33612, USA
| |
Collapse
|
46
|
Debata PR, Curcio GM, Mukherjee S, Banerjee P. Causal Factors for Brain Tumor and Targeted Strategies. SPRINGER PROCEEDINGS IN PHYSICS 2014. [DOI: 10.1007/978-3-319-02207-9_19] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
|
47
|
Le Guen T, Jullien L, Schertzer M, Lefebvre A, Kermasson L, de Villartay JP, Londoño-Vallejo A, Revy P. [RTEL1 (regulator of telomere elongation helicase 1), a DNA helicase essential for genome stability]. Med Sci (Paris) 2013; 29:1138-44. [PMID: 24356145 DOI: 10.1051/medsci/20132912018] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
RTEL1 (regulator of telomere length helicase 1) is a DNA helicase that has been identified more than 10 years ago. Many works since, mainly in the nematode Caenorhabditis elegans and the mouse, have highlighted its role in chromosomal stability, maintenance of telomere length, and DNA repair. Recently, four laboratories have characterized RTEL1 mutations in patients with dyskeratosis congenita (DC) and Hoyeraal-Hreidarsson (HH) syndrome, a rare and severe variant of DC. We here summarize the current knowledge on RTEL1 and discuss the possible other functions that RTEL1 could play.
Collapse
Affiliation(s)
- Tangui Le Guen
- Dynamique du génome et système immunitaire, Institut Imagine, 149, rue de Sèvres, 75015 Paris, France - Inserm U768, université Paris Descartes, Sorbonne Paris Cité, Institut Imagine, 149, rue de Sèvres, 75015 Paris, France
| | - Laurent Jullien
- Dynamique du génome et système immunitaire, Institut Imagine, 149, rue de Sèvres, 75015 Paris, France - Inserm U768, université Paris Descartes, Sorbonne Paris Cité, Institut Imagine, 149, rue de Sèvres, 75015 Paris, France
| | - Mike Schertzer
- Télomère et cancer, Institut Curie, UMR3244, 26 Rue d'Ulm, 75005 Paris, France
| | - Axelle Lefebvre
- Dynamique du génome et système immunitaire, Institut Imagine, 149, rue de Sèvres, 75015 Paris, France - Inserm U768, université Paris Descartes, Sorbonne Paris Cité, Institut Imagine, 149, rue de Sèvres, 75015 Paris, France
| | - Laetitia Kermasson
- Dynamique du génome et système immunitaire, Institut Imagine, 149, rue de Sèvres, 75015 Paris, France - Inserm U768, université Paris Descartes, Sorbonne Paris Cité, Institut Imagine, 149, rue de Sèvres, 75015 Paris, France
| | - Jean-Pierre de Villartay
- Dynamique du génome et système immunitaire, Institut Imagine, 149, rue de Sèvres, 75015 Paris, France - Inserm U768, université Paris Descartes, Sorbonne Paris Cité, Institut Imagine, 149, rue de Sèvres, 75015 Paris, France - Hôpital Necker-Enfants malades, AP-HP, service d'immunologie et d'hématologie pédiatriques, 149, rue de Sèvres, 75015 Paris, France
| | | | - Patrick Revy
- Dynamique du génome et système immunitaire, Institut Imagine, 149, rue de Sèvres, 75015 Paris, France - Inserm U768, université Paris Descartes, Sorbonne Paris Cité, Institut Imagine, 149, rue de Sèvres, 75015 Paris, France
| |
Collapse
|
48
|
Vannier JB, Sandhu S, Petalcorin MIR, Wu X, Nabi Z, Ding H, Boulton SJ. RTEL1 is a replisome-associated helicase that promotes telomere and genome-wide replication. Science 2013; 342:239-42. [PMID: 24115439 DOI: 10.1126/science.1241779] [Citation(s) in RCA: 158] [Impact Index Per Article: 14.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Regulator of telomere length 1 (RTEL1) is an essential DNA helicase that disassembles telomere loops (T loops) and suppresses telomere fragility to maintain the integrity of chromosome ends. We established that RTEL1 also associates with the replisome through binding to proliferating cell nuclear antigen (PCNA). Mouse cells disrupted for the RTEL1-PCNA interaction (PIP mutant) exhibited accelerated senescence, replication fork instability, reduced replication fork extension rates, and increased origin usage. Although T-loop disassembly at telomeres was unaffected in the mutant cells, telomere replication was compromised, leading to fragile sites at telomeres. RTEL1-PIP mutant mice were viable, but loss of the RTEL1-PCNA interaction accelerated the onset of tumorigenesis in p53-deficient mice. We propose that RTEL1 plays a critical role in both telomere and genome-wide replication, which is crucial for genetic stability and tumor avoidance.
Collapse
Affiliation(s)
- Jean-Baptiste Vannier
- DNA Damage Response Laboratory, London Research Institute, Cancer Research UK, Clare Hall, South Mimms, UK
| | | | | | | | | | | | | |
Collapse
|
49
|
Ballew BJ, Joseph V, De S, Sarek G, Vannier JB, Stracker T, Schrader KA, Small TN, O'Reilly R, Manschreck C, Harlan Fleischut MM, Zhang L, Sullivan J, Stratton K, Yeager M, Jacobs K, Giri N, Alter BP, Boland J, Burdett L, Offit K, Boulton SJ, Savage SA, Petrini JHJ. A recessive founder mutation in regulator of telomere elongation helicase 1, RTEL1, underlies severe immunodeficiency and features of Hoyeraal Hreidarsson syndrome. PLoS Genet 2013; 9:e1003695. [PMID: 24009516 PMCID: PMC3757051 DOI: 10.1371/journal.pgen.1003695] [Citation(s) in RCA: 92] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2013] [Accepted: 06/11/2013] [Indexed: 11/18/2022] Open
Abstract
Dyskeratosis congenita (DC) is a heterogeneous inherited bone marrow failure and cancer predisposition syndrome in which germline mutations in telomere biology genes account for approximately one-half of known families. Hoyeraal Hreidarsson syndrome (HH) is a clinically severe variant of DC in which patients also have cerebellar hypoplasia and may present with severe immunodeficiency and enteropathy. We discovered a germline autosomal recessive mutation in RTEL1, a helicase with critical telomeric functions, in two unrelated families of Ashkenazi Jewish (AJ) ancestry. The affected individuals in these families are homozygous for the same mutation, R1264H, which affects three isoforms of RTEL1. Each parent was a heterozygous carrier of one mutant allele. Patient-derived cell lines revealed evidence of telomere dysfunction, including significantly decreased telomere length, telomere length heterogeneity, and the presence of extra-chromosomal circular telomeric DNA. In addition, RTEL1 mutant cells exhibited enhanced sensitivity to the interstrand cross-linking agent mitomycin C. The molecular data and the patterns of inheritance are consistent with a hypomorphic mutation in RTEL1 as the underlying basis of the clinical and cellular phenotypes. This study further implicates RTEL1 in the etiology of DC/HH and immunodeficiency, and identifies the first known homozygous autosomal recessive disease-associated mutation in RTEL1.
Collapse
Affiliation(s)
- Bari J. Ballew
- Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, United States of America
| | - Vijai Joseph
- Clinical Genetics Service, Department of Medicine, Memorial Hospital, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America
| | - Saurav De
- Molecular Biology Program, Sloan Kettering Institute, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America
| | - Grzegorz Sarek
- DNA Damage Response Laboratory, London Research Institute, Cancer Research UK, South Mimms, United Kingdom
| | - Jean-Baptiste Vannier
- DNA Damage Response Laboratory, London Research Institute, Cancer Research UK, South Mimms, United Kingdom
| | - Travis Stracker
- Molecular Biology Program, Sloan Kettering Institute, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America
| | - Kasmintan A. Schrader
- Clinical Genetics Service, Department of Medicine, Memorial Hospital, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America
| | - Trudy N. Small
- Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America
| | - Richard O'Reilly
- Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America
| | - Chris Manschreck
- Clinical Genetics Service, Department of Medicine, Memorial Hospital, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America
| | - Megan M. Harlan Fleischut
- Clinical Genetics Service, Department of Medicine, Memorial Hospital, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America
| | - Liying Zhang
- Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America
| | - John Sullivan
- Clinical Genetics Service, Department of Medicine, Memorial Hospital, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America
| | - Kelly Stratton
- Clinical Genetics Service, Department of Medicine, Memorial Hospital, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America
| | - Meredith Yeager
- Cancer Genomics Research Laboratory, SAIC-Frederick, Inc., NCI-Frederick, Frederick, Maryland, United States of America
| | - Kevin Jacobs
- Cancer Genomics Research Laboratory, SAIC-Frederick, Inc., NCI-Frederick, Frederick, Maryland, United States of America
| | - Neelam Giri
- Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, United States of America
| | - Blanche P. Alter
- Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, United States of America
| | - Joseph Boland
- Cancer Genomics Research Laboratory, SAIC-Frederick, Inc., NCI-Frederick, Frederick, Maryland, United States of America
| | - Laurie Burdett
- Cancer Genomics Research Laboratory, SAIC-Frederick, Inc., NCI-Frederick, Frederick, Maryland, United States of America
| | - Kenneth Offit
- Clinical Genetics Service, Department of Medicine, Memorial Hospital, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America
- Cancer Genetics and Biology Program, Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America
| | - Simon J. Boulton
- DNA Damage Response Laboratory, London Research Institute, Cancer Research UK, South Mimms, United Kingdom
| | - Sharon A. Savage
- Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, United States of America
| | - John H. J. Petrini
- Molecular Biology Program, Sloan Kettering Institute, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America
| |
Collapse
|
50
|
Abstract
Helicases have major roles in genome maintenance by unwinding structured nucleic acids. Their prominence is marked by various cancers and genetic disorders that are linked to helicase defects. Although considerable effort has been made to understand the functions of DNA helicases that are important for genomic stability and cellular homeostasis, the complexity of the DNA damage response leaves us with unanswered questions regarding how helicase-dependent DNA repair pathways are regulated and coordinated with cell cycle checkpoints. Further studies may open the door to targeting helicases in order to improve cancer treatments based on DNA-damaging chemotherapy or radiation.
Collapse
Affiliation(s)
- Robert M Brosh
- Laboratory of Molecular Gerontology, National Institute on Aging, National Institutes of Health, NIH Biomedical Research Center, 251 Bayview Boulevard, Baltimore, Maryland 21224, USA.
| |
Collapse
|